Clinical Trial Protocol: PER977-02-011
Study Title: Phase [ADDRESS_435148]
Document Date: Version 4: 02May2019
NCT: [STUDY_ID_REMOVED]
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 1 of 93 Clinical Trial Protocol: PER977-02-011  
Study Title:  Phase [ADDRESS_435149]   
Study Number:  PER977 -02-011 
Study Phase:  [ADDRESS_435150] Name:  [CONTACT_350077]:  117,224  
Indication:  Reversal of edoxaban , rivaroxaban, api[INVESTIGATOR_3822] , dabigatran, or 
enoxaparin -induced anticoagulation when medically indicated.  
Investigators:  
Sponsor:  Perosphere Inc. , a wholly -owned subsidiary of AMAG 
Pharmaceutical  
Sponsor Contact:  
[CONTACT_25290]:  
Protocol Version:  4 
Date  
Version 4: 02May2019  
Confidentiality Statement 
Acceptance of this document constitutes the agreement by [CONTACT_1955][INVESTIGATOR_350003].  except that 
this document may be disclosed to appropria te Institutional Review Boards/Institutional Ethics Committee  so 
long as they and anyone else to whom this Protocol may be made available are informed that this is considered 
confidential information within the meaning of the Federal Food, Drug, and Cosmet ic Act [21 U.S.C. 331 (j)], 
the Freedom of Information Act (5 U.S.C. 552) or the Trade Secrets Act (18 U.S.C. 1905), and may not be 
revealed or disclosed without prior written authorization of Perosphere Inc., Danbury CT [ZIP_CODE].  Any 
secondary recipi[INVESTIGATOR_350004] a 
confidential communication and agree to keep it confidential in the same manner in which the recipi[INVESTIGATOR_184710].   

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435151], Medical 
Monitor, Protocol Version Number Change from: 
Investigators:  
Sponsor: Perosphere, Inc 
Sponsor Contact:  
[CONTACT_25290]:  
Protocol Version: 3  
To: 
Investigators:  
Sponsor: Perosphere Inc., a wholly owned subsidiary of AMAG 
Pharmaceutical  
Sponsor Contact:  
[CONTACT_25290]:  
Protocol Version: 4  
Date of final document 
 
Summary of Main Changes Made in Version 2.0 to Generate Version 3.0  
Item  Revision in Version 3.0  
Inclusion criteria #6  
in Synopsis on page 15 
and section 4.3 on page 
46 To modify Pregnancy Screen procedures.  
Changed from 
“Female subjects must have a negative urine pregnancy test at 
screening AND: be surgically sterile (with documentation of 
hysterectomy, bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], bilateral tubal ligation/tuba l occlusion) OR post-menopausal (no 
menstruation for a minimum of 12 months and confirmed by [CONTACT_9284] [FSH] of ≥ 40 mIU/ml) OR, if of child-bearing 
potential, must be using an acceptable method of contraception such as 
an IUD, implant or contraceptive injection, or two forms of the following (e.g., diaphragm, cervical cap, patch or vaginal hormonal 
contraceptive, condom, spermicide, or sponge) for the last three 
months, OR in a  monogamous relation with a male partner who has 
undergone a documented vasectomy a minimum of [ADDRESS_435152] agree to continue to use their method of birth control for the duration of the study and for a 
minimum of one complete menstrual cycle or 28 days following 
discharge from the study” 
to  
“Female subjects must have negative pregnancy test s at screening and 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 7 of 93 Item  Revision in Version 3.0  
Section 6.2 Medical 
History on page 5 3 To include that subjects will need to sign a medical release.  
Added “ To ensure subject safety, the Investigator may ask the subject 
to sign a medical release form allowing him to contact [CONTACT_423]'s 
doctor for more information about subject's medical history. ” 
Section 6.6.2 Laboratory 
Parameters on page 55 To modify Pregnancy Screen portion of the table. 
Changed from:  
PREGNANCY SCREE N** (to be performed at screening, check -in, 
and discharge)  
Urine pregnancy test (females only)  
FSH will be done on post -menopausal females  
**the pregnancy tests may be performed in -clinic using CLIA -waived 
marketed kits.  
To 
PREGNANCY SCREEN** (females only)  
Urine pregnancy tests will be performed at screening and at discharge.  
Serum pregnancy test will be done at check -in on Day -1.  
FSH and estradiol tests will be done on post -menopausal females  at 
screening and check- in on Day - 1. 
**the urine pregnancy tests may be performed in -clinic using CLIA -
waived marketed kits.  
 
Section 7.1 Screening 
Visit (Day -36 to -1) on 
page 6 8 To modify pregnancy screen procedure at screening . 
Added: “ FSH and Estradiol test for post -menopausal female subjects” 
Section 7.2.1 Check -in 
(Day -1) Procedures on 
page 69 To modify pregnancy screen procedure at check-in on Day -1. 
 
Changed from “ Urine  pregnancy for all female subjects” to “ serum 
pregnancy tests  in all female subjects ” 
Added: “ FSH and Estradiol tests for post -menopausal female subjects” 
9.[ADDRESS_435153] and clarify criteria for api[INVESTIGATOR_350005] -responder. 
Changed from: “ The anticoagulant effect of api[INVESTIGATOR_350006]- PER977 (four hours) 
versus baseline (pre-api[INVESTIGATOR_350007]-dose on Day 3).  For 
the purposes of the PD analyses, subjects with percent -of-baseline 
WBCT at pre -PER977 ≤125% (i.e.,  ≤25% increase) will be considered 
as api[INVESTIGATOR_350005] -responders and will be excluded from all PD 
summaries and assessments. ” 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 8 of 93 Item  Revision in Version 3.0  
To “The anticoagulant effect of api[INVESTIGATOR_350008]-PER977 (three hours post-
api[INVESTIGATOR_350009] 4) versus baseline (pre-api[INVESTIGATOR_350010] 1).  For the purposes of the PD analyses, subjects with percent-of- baseline WBCT at pre-PER977<120% (i.e., < 20% 
increase) will be considered as api[INVESTIGATOR_350005]-responders and will b e 
excluded from all PD summaries and assessments. ” 
Section 9.8 Statistical 
Analysis of the Primary 
PD End Point (WBCT) on 
page 8 2 To clarify statistical analysis and definition of reversal of anticoagulation 
Change section title from “9.8 Categorical Analysis of the Primary PD 
Endpoint (WBCT) ” to “9.8 Analysis of the Primary PD Endpoint 
(WBCT) ” 
Changed from “ Complete reversal is defined as mean WBCT to 
≤110% of baseline up to and including [ADDRESS_435154] article 
administration.” 
To “Complete reversal is achieved for a treatment group or for a 
subject if the mean WBCT is ≤ 110% of baseline at any post -baseline 
time point up to and including [ADDRESS_435155] is <=110% of 
baseline at any  post-baseline time point up to and including [ADDRESS_435156] article administration. ” 
Changed from “ Complete and sustained reversal of anti- coagulation is 
defined as a return of mean WBCT to ≤115% of baseline at all time 
points between [ADDRESS_435157] article administration. ” 
To “Complete and sustained reversal of anti- coagulation is achieved 
for a treatment group if the mean WBCT is ≤ 115% of baseline at all 
time points between 1 and 5 hours (inclusive) following test article 
administration. Complete and sustained reversal of anti- coagulation is 
achieved for a subject if WBCT is ≤  115% of baseline at all time 
points between 1 and 5 hours (inclusive) following test article administration .”
 
 
Summary of Main Changes Made in Version 1.0 to Generate Version 2.0  
Item  Revision in Version 2.0  
Dose Schema:  
In Synopsis and s ection 3.1  
 Dosing schema was revised.  The version 2.0 dosing schema 
was replaced with following dosing schema.  
 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 9 of 93 Item  Revision in Version 2.0  
Api[INVESTIGATOR_350011]:  
1. In Synopsis  
2. In Study Procedure 
3. In section 2  
4. In section 3.1  
5. In section 5.2.3  
6. In section 5.3  
7. In section 7.2.2  
8. In section 7.2.3  
9. In section [IP_ADDRESS]  Increase api[INVESTIGATOR_350012] 5 mg BID (Q12) for 3.5 days 
as a single oral tablet to 10 mg BID (Q12) for 3.5 days as two 
oral tablets  
Exclusion Criteria #3  Clarify exclusion criteria  
Changed from  
“History of major bleeding, trauma, or surgical procedure of 
any type ” to “History of major bleeding, trauma, or 
surgical procedure of any type based on PI [INVESTIGATOR_9106]” 
Stroke Assessment:  
In Synopsis Add stroke assessment  
Add in Safety Assessments: “Stroke assessment”  
Stroke Assessment  
In Study Procedures Add stroke assessment  
Add stroke assessment in Study Procedure Table on Day 1 to 4 
Add in k: “Stroke assessments will be performed by [CONTACT_976] [INVESTIGATOR_350013] [ADDRESS_435158]- api[INVESTIGATOR_350014] (±1-hour window) on Day 1 to 4.” 
Stroke Assessment  
In section 6.5 Add section 6.5 Stroke Assessment  
Add: 
“Stroke assessments will be performed by [CONTACT_976] [INVESTIGATOR_350015] [ADDRESS_435159]-api[INVESTIGATOR_350016] (±1-
hour window) on Day 1 to 4.  PI [INVESTIGATOR_350017]: 
Stroke warning signs:  
• Sudden weakness or numbness of the face, arm or leg, especially on one side 
• Sudden confusion or difficulty understanding 
• Trouble speaking, walking or seeing 
• Dizziness or loss of balance 
• Sudden onset of severe headache  
Physical symptoms : 
• Facial smiling or showing of teeth on one side 
• One arm does not move or drifts com pared to the other 
on extension  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 10 of 93 Item  Revision in Version 2.0  
• Abnormal slurred speech, improper choice of words, 
inability to speak or acute confusion and disorientation ”   
Stroke Assessment  
1. In section 7.2.2.  
2. In section 7.2.3.  
3. In section [IP_ADDRESS]  
 Add stroke assessment  
Add: “ Stroke assessment at approximately [ADDRESS_435160] -
api[INVESTIGATOR_350016] (±1-hour window)” 
 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435161] OF ABBREVIATION S AND DEFINITIONS OF  TERM S ..........................................25  
1 INTRODUCTION  ...........................................................................................................28  
1.1 Clinical Problem ....................................................................................................28  
1.2 Clinical Development of Ciraparantag  ..................................................................29  
1.2.1  PER977-01-001............................................................................................29  
1.2.2  PER977-01-002............................................................................................33  
1.2.3  PER977-01-003............................................................................................34  
1.2.4  PER977-02-001............................................................................................37  
1.2.5  Pharmacokinetics  .........................................................................................40  
2 STUDY OBJECTIVES  ....................................................................................................44  
3 INVESTIGATIONAL PLAN  ..........................................................................................45  
3.1 Overall Study Design and Plan  ..............................................................................45  
3.2 Dose Rationale  .......................................................................................................46  
3.3 Study Duration and Dates  ......................................................................................46  
4 STUDY POPULATION  ..................................................................................................47  
4.1 Screening and Enrollment  ......................................................................................47  
4.2 Study Population ....................................................................................................47  
4.3 Inclusion Criteria  ...................................................................................................47  
4.4 Exclusion Criteria  ..................................................................................................48  
5 STUDY TREATMENT(S)  ..............................................................................................50  
5.1 Description of Treatment(s)  ...................................................................................[ADDRESS_435162] ...................................51  
5.4 Method of Assigning Patients to Treatment Groups ..............................................51  
5.5 Blinding..................................................................................................................51  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 12 of 93 5.6 Concomitant Therapy .............................................................................................51  
5.7 Meals and Study Restrictions .................................................................................52  
5.7.1  Dietary Guidelines Prior to Check -in ..........................................................52  
5.7.2  Dietary Guidelines during the Study ............................................................52  
5.7.3  Lifestyle Restrictions  ...................................................................................52  
5.8 Treatment Compliance  ...........................................................................................53  
5.9 Dose Escalation/De -Escalation  ..............................................................................[ADDRESS_435163] Retention at Study Site  ....................................................54  
6 STUDY PROCEDURES  .................................................................................................55  
6.1 Informed Consent ...................................................................................................55  
6.2 Medical History  .....................................................................................................55  
6.3 Physical Examination .............................................................................................55  
6.4 Vital Signs  ..............................................................................................................55  
6.5 Stroke Assessments ................................................................................................56  
6.6 Clinical Laboratory Tests  .......................................................................................57  
6.6.1  Fecal Occult Blood Tests  .............................................................................57  
6.6.2  Laboratory Parameters  .................................................................................58  
6.6.3  Experimental Safety Biomarker Assessment  ...............................................59  
6.7 Electrocardiograms  ................................................................................................59  
6.8 Dispensing Study Drug ..........................................................................................59  
6.8.1  Ciraparantag  .................................................................................................59  
6.8.2  Placebo  .........................................................................................................60  
6.8.3  Api[INVESTIGATOR_3822]  ......................................................................................................60  
6.9 Efficacy Assessments .............................................................................................60  
6.9.1  Pharmacokinetic Assessment  .......................................................................60  
6.9.2  Pharmacodynamic Assessment  ....................................................................61  
6.10  Adverse Events Assessments .................................................................................61  
6.10.1  Clinical Laboratory Abnormalities and Other Abnormal 
Assessments as Adverse Events or Serious Adverse Events .......................62  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 13 of 93 6.10.2  Toxicity Management  ..................................................................................62  
6.10.3  Adverse Event (AE)  .....................................................................................63  
6.10.4  Serious Adverse Event (SAE) ......................................................................63  
6.10.5  AE Severity  ..................................................................................................64  
6.10.6  Causality Assessment ...................................................................................64  
6.10.7  Action Taken Regarding the Study Drug.....................................................64  
6.10.8  Adverse Event Outcome ..............................................................................65  
6.10.9  Other Action Taken for Event ......................................................................65  
6.10.10  Serious Adverse Event Reporting–Procedure for Investigators ..................66  
6.10.11  Notifying Regulatory Authorities, Investigators, and IR B/IEC ...................[ADDRESS_435164] Replacement  ....................................................................................69  
7 STUDY ACTIVITIES  .....................................................................................................70  
7.1 Screening Visit (Days -36 to -1) ............................................................................70  
7.2 Treatment Period (Day -1 to Day 5) ......................................................................70  
7.2.1  Check -in (Day -1) Procedures .....................................................................70  
7.2.2  Day 1 Procedures  .........................................................................................71  
7.2.3  Day 2 and Day 3 Procedures ........................................................................71  
7.2.4  Day 4 Procedures  .........................................................................................72  
7.2.5  Day 5 or Early Termination Procedures ......................................................74  
7.3 Follow-up (Day 7-10) ............................................................................................[ADDRESS_435165] Keepi[INVESTIGATOR_007]  .....................................................................................................78  
8.6 Document Retention ..............................................................................................78  
9 PLANNED STATISTICAL METHODS  ........................................................................79  
9.1 General Considerations ..........................................................................................79  
9.2 Determination of Sample Size  ...............................................................................79  
9.3 Analysis Populations ..............................................................................................79  
9.4 Pharmacokinetics of PER977 and Metabolite (BAP) ............................................80  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 14 of 93 9.5 Plasma Api[INVESTIGATOR_350018]  ......................................................................82  
9.6 Dose Proportionality ..............................................................................................82  
9.7 Pharmacodynamic Analyses  ..................................................................................83  
9.8 Analysis of the Primary PD Endpoint (WBCT) ....................................................[ADDRESS_435166] of the Study .................................................................................88  
10.5  Patient Information and Consent  ...........................................................................88  
10.6  Patient Confidentiality  ...........................................................................................89  
10.7  Regulatory Compliance .........................................................................................89  
10.8  Case Report Forms and Study Records  .................................................................90  
10.9  Protocol Violations/Deviations  ..............................................................................[ADDRESS_435167] OF APPENDICES  
Appendix 1  Sponsor and Investigator Signatures ..................................................92  
 
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435168] OF TABLES 
Table 1:  Number of Subjects with Return to Within 20% of Baseline WBCT 
by [CONTACT_184734] ...................................................................................32  
Table 2:  Summary of TEAEs by [CONTACT_350064]  .....................................................................................................................[ADDRESS_435169] OF FIGURES  
Figure 1:  WBCT Following a Single IV Dose of Ciraparantag Acetate 
(PER977) Versus Pooled Placebo Data in Subjects Admi nistered a Single Oral 
Dose of Edoxaban 60 mg .............................................................................................31  
Figure 2:  Percent of Baseline (A -B) WBCT for All Treatments .................................36  
Figure 3:  Ciraparantag* Serum Concentration Profile ................................................41  
Figure 4:  BAP Serum Concentration Profile* .............................................................42  
Figure 5:  Ciraparantag* Urinary Excretion Profile as BAP  ........................................42  
Figure 6:  Study Schema ...............................................................................................45  
 
 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 16 of 93 SYNOPSIS  
Sponsor:  
Perosphere Inc. , a wholly-owned subsidiary of AMAG Pharmaceutical 
Name [CONTACT_184777] : 
Ciraparantag, PER977 
Study Title:  
Phase [ADDRESS_435170]  
Study Number:  
PER977-02-011 
Study Phase: 2  
Study Design:  
This study is  a randomized, single-blind, placebo-controlled study to assess the efficacy 
and safety of ciraparantag administered to healthy volunteers anticoagulated with 
api[INVESTIGATOR_350019] B lood Clotting Time (WBCT).  All 
subjects will undergo screening up to [ADDRESS_435171] within 3 week s 
prior to check-in, the check-in procedures may be modified to exclude redundant 
procedures ( safety laboratory tests,  ECG, and physical examination) at the discretion of 
the Investigator.  There will be a safety review after  completion of treatment in one 
cohort and the initiation of treatment in the subsequent cohort. 
Subjects (n=16 per cohort) will be randomized in a 3:1 ratio to receive ciraparantag or 
placebo (saline for injection).  For the dosing schema, please refer to the figure below.  
All subjects will receive 10 mg api[INVESTIGATOR_292928] 3.5 days ( Twice daily Q12  on Days 1-3 and 
once on the morning of Day 4).  On Day 4, approximately  3 hours after administering 
api[INVESTIGATOR_3822], study drug or placebo will be intravenously (IV)  administered.  Study drug or 
placebo will be administered only to those subjects who have a minimum increase in 
clotting time of 20% (as measured by  [CONTACT_184736] ) above Day 1 pre -api[INVESTIGATOR_350020]-study drug (i.e., 2.[ADDRESS_435172]- api[INVESTIGATOR_3822] ) time point on Day 4.  Any subject who 
does not have a minimum increase in clotting time of 20% above the Day [ADDRESS_435173] who discontinues prior to completion for reasons other than an adverse event (AE) will be replaced and the replacement subject will receive the same treatment as the original 
subject.  Subjects who discontinue due to an AE that precedes administration of study 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 17 of 93 drug may be replaced at the discretion of the Sponsor.  Subjects who discontinue due to 
AEs that follow administration of study drug will not be replaced.   
A complete s chedule of events for Cohort 1-3 is provided. 
Throughout this protocol, the active study drug doses are expressed as active drug moiety 
(ciraparantag) (as opposed to previously used ciraparantag acetate salt).  The administered dose is based on a concentra tion of 6 mg/mL ciraparantag (active moiety) 
and translates to the following dose conversions from previously used dose identifications:  
Ciraparantag Acetate  Ciraparantag  Dose Volume  
[ADDRESS_435174] dose.  
Dose Rationale 
A total of three dosing cohorts (Cohorts 1-3) are planned.  The planned doses of 
ciraparantag or placebo (administered as a volume equivalent of ciraparantag) have been evaluated as single and repeat IV doses from  5 mg ciraparantag acetate (3 mg 
ciraparantag) up to 600 mg ciraparantag acetate (360 mg ciraparantag) in previous protocols (PER977-01-001, PER977-01-002, PER977-01-003, and PER977-02-001).   
Primary Objective(s):  
The primary objectives of this study are: 
• To evaluate the efficacy of ciraparantag in the reversal of anticoagulation induced by 
[CONTACT_9674][INVESTIGATOR_3822] 10 mg BID (Q12) at steady state as assessed by [CONTACT_184736].  
• To evaluate the safety and tolerability of ciraparantag 60 mg (100 mg), 120 mg (200 
mg), and 30 mg (50 mg), and additional cohorts if necessary  approximately 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 18 of 93 administered 3 hours after  10 mg apix aban administration at steady state . 
• To assess the PK characteristics of api[INVESTIGATOR_350021] , 1,4-Bis(3 -aminopropyl) pi[INVESTIGATOR_3746]  (BAP) . 
Eligibility  
Inclusion Criteria  
1. Adults age 50 to 75 years, inclusive 
2. Laboratory tests  (chemistry, hematology and  coagulation assessments) and 
urinalysis performed during screening up to 36 days prior to administration of 
study treatment deemed  not clinically significant by [CONTACT_62674]. 
3. No clinically significant findings on 12- lead electrocardiogram ( ECG) performed 
during screening 
4. Body mass index (BMI) 18 to ≤ 32 kg/m2, inclusive 
5. Male subjects agree to use appropriate contraception (i.e., latex condom with spermicide) in addition to their partner using an acceptable form of contraception (e.g., diaphragm, cervical cap, intrauterine device, hormonal contraceptives, surgical sterilization or post-menopausal), when engaging in sexual activity during the course of the study. Moreover, male subjects should not donate sperm or attem pt to impregnate a partner during the course of the study and for a period 
of [ADDRESS_435175] s at screening and at check -in 
AND: be surgically sterile  at least [ADDRESS_435176] dose  (with 
documentation of hysterectomy, bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], bilateral tubal ligation/tubal occlusion) ; OR post-menopausal (no menstruation for 
a minimum of 12 months and confirmed by [CONTACT_9284] [FSH] of ≥ 40 m IU/ml and serum estradiol < 30 pg/ml), OR  if of child -bearing potential, 
must be using an acceptable method of contraception such as an IUD, implant or contraceptive injection, or two  forms of the following (e.g., diaphragm, cervical 
cap, patch or  vaginal hormonal contraceptive, condom, spermicide, or sponge) for 
the last three months . All females must agree to continue to use their method of 
birth control for the duration of the study and for a minimum of one complete menstrual cycle .  
7. Subjects wh o have participated in a prior study of ciraparantag must have been 
discharg ed from the study a minimum of [ADDRESS_435177] be willing to  sign the informed consent form indicating voluntary 
consent to participate in the study prior to initiation of screening or study- related 
activities  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 19 of 93 Exclusion Criteria  
1. History or current evidence of clinically significant cardiac, hepatic, renal, 
pulmonary, endocrine, neurologic, infectious, gastrointestinal (including gallbladder disease or surgery) , hematologic, or oncologic disease as determined 
by [CONTACT_184739], physical examination, laboratory test results or 12- lead ECG 
assessment.  History or cu rrent evidence of liver function tests greater than 50% 
of the upper limit of normal (ULN) or renal function tests (serum creatinine) greater than 1.5 mg/dl and based on PI [INVESTIGATOR_9106]. History or current evidence of QTc (QTcF) greater than normal ( 450 msec for males or 470 msec for females).  
2. History of unexplained syncope 
3. History of major bleeding, trauma, or surgical procedure of any type based on PI [INVESTIGATOR_9106]  
4. Vaginal  delivery within six months prior to screening  
5. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) within one year prior to screening  
6. Long standing history of bleeding epi[INVESTIGATOR_184713], bruising or gingival bleeding or if not long standing, within [ADDRESS_435178] not undergone hysterectomy, including history of menorrhagia (heavy menstrual bleeding), meno metro rrhagia or polymenorrhea  
9. Smokers or use of tobacco and/or nicotine containing products within [ADDRESS_435179]’s verbal history 
10. Pregnant or breast -feeding  
11. Males with a history of hormone therapy within [ADDRESS_435180] or anticoagulant within 3 months prior to 
study entry or any non- steroidal anti -inflammatory drug or cyclooxygenase 
inhibitor within 2 weeks prior to dosing 
13. Taking any type of chronic medication (including vitamin, nutritional and herba l 
supplements) for more than 14 consecutive days within the 4 weeks prior to study entry (use of hormonal contraceptives is acceptable except for oral contraceptives ) 
 
14. Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus antibody (HCV -Ab), or Hepatitis B surface antigen (HBsAg)  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 20 of 93 15. Donation of blood or blood products within 56 days prior to screening  
16. Participation in any study with an investigational compound or device within 30 
days prior to signing informed consent  
17. Active drug or alcohol dependence within the prior 12 months or any condition that, in the opi[INVESTIGATOR_689], would interfere with adherence to study protocol 
18. Allergic to api[INVESTIGATOR_350022]:  
No formal sample size calculations were performed for this st udy; sixteen  (16) subjects 
enrolled in each cohort (3:1; active: placebo) is  considered adequate to achie ve the 
objectives of the study. 
Estimated number of subjects screened:  120 
Planned number of subjects randomized:  48 
Planned number of evaluable subjects:  [ADDRESS_435181], Dose, and Mode of Administration: 
The following dosage forms will be provided for this study: 
• Ciraparantag for IV inje ction  
• Placebo  saline  for IV injection  
• Api[INVESTIGATOR_3822] 5 mg tablets ( ELIQUIS® [COMPANY_007]/BMS ) for oral administration  
All doses of study drug (ciraparantag or placebo) will be administered by [CONTACT_51215] 
(over a minimum of 10 minutes) into an indwelling catheter . The indwelling catheter will 
be flushed with 5.0 mL of sterile 0.9% Sodium Chloride Injection, USP before and  after 
administration of study drug. All doses of study drug will be administered in a single -
blinded-fashion.  
Duration of Treatment:  
Expectation of the total duration of the study is up to approximately [ADDRESS_435182] participation is approximately 50 days inclusive of screening and follow-up.  Subjects enrolled will spend up to 5 nights admitted to an in -patient facility.
   
Concomitant Medications : 
Use of concomitant medications (including vitamin, nutritional and herbal supplements) is prohibited as per Exclusion criteria, during screening and for the course of the study. Acetaminophen up to 1 gram/24 hours may be administered as needed for treatment at 
the discretion of the Investigator.  As needed use of over-the- counter antihistamines  
during screening, prior to admission on Day -1, and following discharge from the clinic site on Day 5 is permitted. U se of hormonal contraceptives is acceptable except for oral 
contraceptives . 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 21 of 93 Pharmacokinetic Assessment:  
Api[INVESTIGATOR_350023]: 
Day 1: pre -api[INVESTIGATOR_3822] (within 1 hr. prior to dosing) 
Day 4: post- api[INVESTIGATOR_350024] 2.[ADDRESS_435183]-study drug at 15, 30, 45 minutes, and 1, 3, 5, 
24 hrs.  
Ciraparantag  and BAP  PK time points:  
Day 4: pre -study drug (within 1 hr. prior to dosing of ciraparantag or placebo) and  
post-study drug at 15, 30, 45 minutes, and 1, 3, 5, 24 hrs. 
Pharmacodynamic Assessments:  
WBCT time points: 
Day 1: pre -api[INVESTIGATOR_350025] (within 1 hr. prior to dosing) 
Day 4: post- api[INVESTIGATOR_350024] 2.[ADDRESS_435184]-study drug at 15, 30, 45 minutes, and 1, 3, 5, 
24 hrs. (only subjects with at least 20% increase of clotting time from the Day 1 pre -
api[INVESTIGATOR_350026]). 
Safety Assessments:  
The following parameters will be assessed:  
• Physical examination  
• Vital signs  
• Electrocardiograms (ECGs)  
• Stroke assessment  
• Blood and urine safety laboratories  
• Fecal o ccult blood 
• Expe rimental safety biomarker assessment  
Citrated plasma for e xperimental safety biomarker assessment  will be collected at pre -
api[INVESTIGATOR_3822] (within 1 hr. prior to dosing) on Day 1, and a t 2.75 and 8 hrs. (i.e , [ADDRESS_435185]-
study drug) post- api[INVESTIGATOR_292981] 4. Experimental safety biomarker assessment will be 
done at the PI’s discretion . 
Subjects will be observed for a minimum of [ADDRESS_435186] resolved, coagulation parameters ( WBCT ) are not clinically significant, and no further 
observation is necessary, the subject will be discharged from the facility on Day 5.  
On Day 7 -10, su bjects will be followed -up by [CONTACT_65859].  Subjects will be  discharged 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435187]. 
Statistical Methods:  
All data collected will be presented in data listings.  Data from subjects excluded from an analysis set will be presented in the data listings, but not included in the calculation of summary statistics.  For categorical variables, frequencies, and percentages will be presented.  Continuous variables will be summarized using descriptive statistics (number of subjects, mean, median, standa rd deviation, minimum, and maximum).  Data will be 
tabulated by [CONTACT_3148], across active treatment groups when applicable, with all placebo subjects pooled into a single group. 
All evaluable data from subjects in the analysis sets will be included in the a nalyses.  No 
adjustment or imputation will be utilized for missing values or for subjects who withdraw 
prior to completing the study. 
Baseline values will be defined as the last assessment prior to investigational product 
administration and per period if a pplicable.  
Definition of Reversal of Anticoagulation – Clotting Time by [CONTACT_184736]   
• Complete re versal is defined as a return of mean  WBCT  to ≤110% of baseline up to 
and including [ADDRESS_435188] article administration.  
• Complete and sustained reversal of anti-coagulation is defined as a return of mean 
WBCT  to ≤115% of baseline at all time points between [ADDRESS_435189] 
article administration.  Dose escalation or de- escalation will be determined by [CONTACT_350065].  
Details of all statistical analys es will be specified in a separate statistical analysis plan 
(SAP)  that will be finalized prior to data base lock . 
Date of Original Protocol:  [ADDRESS_435190] 2017  
Prepared in:  Microsoft Word 2013  
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435191] be negative at check -in to continue study participation . In the event an occult blood kit is 
not returned, a rectal exam for stool sample may be performed at the discretion of the Investigator. Following the treatment 
period, coagulation parameters ( WBCT result ) must be not clinically significant prior to discharge.  
g. Urine drug and saliva alcohol tests will be performed at screening and at check -in. A blood sample will be taken to assess the 
presence of HbsAg, HCV- Ab and HIV at screening. 
h. Electrocardiograms (12 -lead) will be performed at screening,  check -in, after receiving api[INVESTIGATOR_350027] [ADDRESS_435192] will be performed at 
check -in on Day - 1. 
j. Subjects will be admitted to the clinical site on Day - 1 for baseline assessments and will remain confined until 24 hours after the 
study  drug administration provided that, in the opi[INVESTIGATOR_689], it is safe to be discharged.  
k. Api[INVESTIGATOR_350028] 10 mg BID ( Q12) after meal  on Days [ADDRESS_435193]-api[INVESTIGATOR_350029] (± 1-hour window)  on Day [ADDRESS_435194]  will be collected on Day 1 pre -api[INVESTIGATOR_3822] (as baseline), Day [ADDRESS_435195] 2 0% increase of clotting time from Day [ADDRESS_435196] resolved to the sa tisfaction of the Investigator.  
 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435197]  aspartate aminotransferase  
AUC  area under the concentration versus time curve  
AV atrioventricular  
BAP  1,4-Bis(3 -aminopropyl)pi[INVESTIGATOR_184714]  
C24 Observed quantifiable analyte concentration in the sampled 
matrix at the [ADDRESS_435198]  
FIIa factor IIa  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 26 of 93 ABBREVIATION  DEFINITION  
FXa factor Xa  
F1.2 prothrombin fragments F1 and 2  
FDA  Food and Drug Administration  
FSH follicle stimulating hormone  
GCP  good clinical practice (refers to ICH and CFR)  
HBsAg  hepatitis B surface antigen  
HCV -Ab hepatitis C virus antibody  
HDPE  high density polyethylene  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
HR heart rate  
ICF informed consent form  
ICH International Conference on Harmonization  
IEC independent ethics committee  
IMPD  Investigational Medicinal Product Dossier  
IND Investigational New Drug  
IRB institutional review board  
IV intravenous  
LMWH  low molecular weight heparin  
LLOQ  lower limit of quantification  
LOQ  limit of quantification  
NOAC  new oral anticoagulants  
NS normal saline  
MedDRA  Medical Dictionary for Regulatory Activities  
PD pharmacodynamic  
PK pharmacokinetic  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435199] operating procedures  
S[LOCATION_003]R  serious unexpected serious adverse reaction  
t1/[ADDRESS_435200]  whole blood clotting time  
WHO  World Health Organization  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 28 of 93 1 INTRODUCTION 
Ciraparantag (PER977) is a small, synthetic water -soluble new molecular entity that 
physically associates with heparins and related anticoagulant drugs (i.e., direct factor Xa  
[FXa] and factor IIa [F IIa] inhibitors) allowing rapid re- establish ment of a normal blood 
coagulation state.  This reversal effect is due to direct non -covalent binding to the 
anticoagulant molecule with no binding to blood coagulation factors or proteins in the 
blood. 
1.1 Clinical Problem 
In the [LOCATION_002], the number of patients requiring anticoagulation annually numbers in the millions; upwards of 600,000 patients with thromboembolic events or pulmonary embolism, ( CDC Fast Stats 2012) and over 1 million joint replacement procedures (knee 
and hip), ( CDC Statistics 2010 ) necessitate prophylactic post -operative anticoagulation, 
and most of the 2.66 million patients with atrial fibrillation will also be prophylactically anticoagulated. ( CDC Atrial Fibrillation Fact Sheet)  
Anticoagulation is time consuming and problematic for both physicians and patients.  The traditional anticoagulants (heparin and warfarin) have a long history of successful clinical use, with an accepted risk of substantial bleeding. ( Palareti G 2011, FDA Safety 
Alert 2012) Due to the incidence of major bl eeding associated with the traditional 
anticoagulants, demand for new therapeutic anticoagulants has been met with the introduction of low molecular weight heparin ( LMWH ) products and selective oral 
inhibitors of clotting factor IIa and Xa.  Although the new oral anticoagulants ( NOACs ) 
have several advantages including rapid therapeutic effectiveness, ease of dosing, and lack of monitoring requirements, each is associated with risk of major bleeding. ( ISMP 
2012)  
A significant obstacle to adoption of the ne w FXa and F IIa inhibitors is clinical concern 
regarding the lack of an effective reversal agent (e.g., vitamin K for warfarin, protamine 
for heparin and LMWH [partial reversal]).  This is germane in cases of overdose, trauma, 
need for emergency or urgent surgery, and in patients undergoing elective procedures (cardiac ablations, endoscopi[INVESTIGATOR_24898], extensive dental surgery) that may require discontinuation, changing, or bridging of anticoagulation.  Current recommendations call for termination of ant icoagulants between 2 – 4 days prior to the elective procedures and 
cautiously keepi[INVESTIGATOR_007] a patient off anticoagulation for some period of time after the procedure, especially if a biopsy or invasive procedure has been used. ( McLean 2012) In 
emergency surgeri es, where it is desirable to wait until at least [ADDRESS_435201] passed 
before surgical intervention, if possible, patients are at risk of significant bleeding. 
An efficacious reversal agent for the LMWHs and oral FXa  and F IIa inhibitors would 
permit rap id reversal of anticoagulation for emergency purposes, minimize the time 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435202] -procedure.   
Equally germane is the issue of identification of biomarkers for both efficacy and safety monitoring for pro-coagulation signals for drugs under development for reversal of anticoagulants.  Many of the commonly used biomarkers (prothrombin time [PT], activated partial thromboplastin time  [aPTT], anti -factor Xa [anti -FXa], etc.) show 
significant disparity between the biomarker’s indication of a reversal and the lack of bleeding cessation , if there is reagent interference.  The primary goal of reversing an 
anticoagulant is simply to return the ability of the blood to clot; historical biomarkers have been used for this purpose but they remain surrogate biomarkers. This problem is addressed by [CONTACT_184736] , which measures clotting time in fresh whole blood samples. 
1.[ADDRESS_435203] 15, 2016, ciraparantag (PER977; previously, aripazine) has been evaluated in four clinical studies of single escalating doses of ciraparantag following administration edoxaban (PER977-01-001; [STUDY_ID_REMOVED]), unfractionated heparin (PER977-01-002; [STUDY_ID_REMOVED]), and enoxaparin (PER977-01-003; [STUDY_ID_REMOVED]), and following anticoagulation and re-anticoagulation with edoxaban (PER977-02-001; [STUDY_ID_REMOVED]).  In this protocol, all doses are listed as the ciraparantag base equivalent.  Both dosing format s are utilized in the presentation of clinical data from previous studies.   
In each of the protocols the dosing of active study drug was described based on the drug substance ciraparantag acetate (salt).  In accordance with new guidelines, the drug substance content is now labeled as active moiety (ciraparantag).  Throughout this document, the active study drug doses are expressed according to the new convention. 
Completed safety and efficacy data from PER977 -01-001, PER977-01-003, and PER977-
02-[ADDRESS_435204] in human, double-blind, placebo-controlled, 
sequential group, two-period, ascending ciraparantag dose study administered alone and in combination with edoxaban in healthy volunteers.  The study consisted of two periods: a single intravenous IV injection of 3 mg, 9 mg, 15 mg, 30 mg, 60 mg, 120 mg or 180 mg ciraparantag, respectively (ciraparantag acetate 5, mg, 15, mg, 25 mg, 50 mg, 100 mg, 200 mg, or 300 mg) alone or place bo with serial PK , pharmacod ynamic (PD), and safety 
monitoring.  After a one-week washout, a single dose of edoxaban [ADDRESS_435205] period, and with serial P K, PD, and safety 
monitoring. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435206] incidence of treatment emergent adverse events (TEAEs) in Period 1 
(ciraparantag monotherapy) were in the system organ class (SOC) of general disorders and administration -site conditions (feeling hot; n=14, 24.1%), and in nervous system 
disorders ( dysg eusia; n=8, 13.8%).  Adverse events in placebo subjects comprised feeling 
cold, headache, infusion related reaction and peripheral coldness reported in one subject each.  
The highest incidence of TEAEs in Period 2 was in the SOC of general disorders and administration -site conditions (feeling hot n=11, 17.2%), nervous system disorders 
(dysgeusia n=8, 12.5%), and in injury, poisonings, and procedural complications (contusion n=7, 10.9%).  Adverse events in placebo subjec ts comprised feeling cold chest 
discomfort, infusion site coldness, vessel puncture site pain, dysgeusia , headache, 
contusion, infusion related reaction, peripheral coldness, and hematoma reported in one subject each.  
No serious AEs were reported during the conduct of the study, no laboratory results were reported as AEs and there were no clinically significant changes in vital signs.  There were no clinically significant AEs and no dose-related findings occurred with regard to interval prolongations in median of triplicate ECG tracings with regard to HR, P -R, QRS, 
QTcF or R -R intervals.  
The protocol initially designated prothrombin time (PT) and thromboelastography reaction time (TEG -R) as the primary PD efficacy variables based on their use in in vitro  
studies.  One of the objectives of the protocol was to assess which biomarkers were the 
best endpoints for future clinical trials.  In seeking a biomarker for ciraparantag reversal effect on anticoagulants, the fact that cationic ciraparantag exhibits strong binding to anionic citrate, ethylene diaminetetra  acetic acid (EDTA), and oxalate due to charge 
interaction became problematic.  Plasma tubes contain a large molar excess of anions that overwhelm and disrupt the ciraparantag-anticoagulant complex rendering the results of plasma -based assays non-representative of physiologic conditions.  Findings in Cohorts 
1-4 of the study indicated that PT and TEG-R would not be acceptable biomarkers in clinical trials due to their insensitivity and high variability.  Whole blood collected in tubes and transported to the laboratory for TEG-R testing were observed to be clotting clinically faster as study drug dose increased, and yet the PT values showed no change and TEG -R showed a high degree of variability between time points and between 
subjects.  Mean PT and TEG-R showed no change over time within cohorts and across escalating dose cohorts.  
Enhanced clotting of anticoagulated blood was observed beginning in Cohort 2 (30 mg ciraparantag [ciraparantag acetate 50 mg]).  Who le blood clotting time (WBCT; referred 
to as ‘venous clotting time’ or ‘VCT’ in the protocol or Lee- White clotting time where -in 
glass is the only activating agent) was performed on discarded blood samples from a few patients.  This was done in order to assess whether blood was clotting slower than baseline with edoxaban administration (e.g., anticoagulation) and possibly returning to 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 31 of 93 baseline after administration of study drug (i.e., reversal of anticoagulation by 
[CONTACT_184740]).  Data from the pi[INVESTIGATOR_350030] a significant increase in clotting time 
with edoxaban and agreement between independent observers.  As a result of these observations, measurement of clotting, glass bead activated clotting time and WBCT were added to the study as additional exploratory biomarkers for Cohorts 6-7 (120 mg ciraparantag [ciraparantag acetate 200 mg] and 180 mg ciraparantag [300 mg ciraparantag acetate], respectively).  
Ciraparantag acetate displayed no pro -coagulant activity as demonstrated by [CONTACT_184741], D-dimer, prothrombin fragments 1 and 2 (F1.2), or tissue factor pathway inhibitor (TFPI) when administered alone in doses ranging from 3 to 180 mg ciraparantag (5 to 300 mg ciraparantag acetate).  
When administered following edoxaban, a single IV dose of ci raparantag acetate 30 mg, 
60 mg, 120 mg, and 180 mg ciraparantag (50 mg, 100 mg, 200 mg and 300 mg ciraparantag acetate) demonstrated reversal of edoxaban -induced anticoagulation versus 
placebo for the full testing period of [ADDRESS_435207]-study drug administration in subjects administered 30 mg to 180 mg ciraparantag (50 to 300 mg ciraparantag acetate).  Initial signs of reversal were noted in Cohort 4 (3 0 mg 
ciraparantag [50 mg ciraparantag acetate]) and full reversal was confirmed with subsequent increasing dose in Cohorts 5 to 7 (60 to 180 mg ciraparantag [100 mg to 300 mg ciraparantag acetate]).  There was no evidence of significant reversal of WBCT in  
subjects who received 15 mg ciraparantag (25 mg ciraparantag acetate) in a repeat cohort of new subjects. 
Figure 1:  WBCT Following a Single IV Dose of Ciraparantag Acetate (PER977) Versus Pooled 
Placebo Data in Subjects Administe red a Single Oral Dose of Edoxaban 60 mg  
 
(Ansell NEJM 2014) 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 32 of 93 Ciraparantag Dose  Ciraparantag 
Acetate Dose  Onset of 
Reversal (min)  Duration of 
Reversal (hr)  
15 mg  (25 mg) NOED  NOED  
30 mg  (50 mg) 30 24 
60 mg  (100 mg) 30 24 
120 mg  (200 mg) 10 24  
180 mg  (300 mg) [ADDRESS_435208] dose  
A dose of 15 mg ciraparantag (equivalent to 25 mg ciraparantag acetate; see conversion 
table above) administered after a single dose of edoxaban [ADDRESS_435209] (percent change from baseline).  The administration of 30 mg ciraparantag (50 mg ciraparantag acetate) (4 subjects) resulted in numerical and statistically significant differences from placebo at 
10 minutes and 60 minutes.  The 60 mg cirapar antag (100 mg ciraparantag acetate) dose 
group showed statistically significant percentage change from baseline compared to placebo at all time points but the [ADDRESS_435210] in subjects who 
received 120 mg and 180 mg ciraparantag (200 mg and 300 mg ciraparantag acetate) 
showed significantly different percentage changes from baseline compared to placebo at 
all time points.  Based on these results, 60 mg ciraparantag (100 mg ciraparantag acetate) was selected as the effective reversal dose.  
Table 1: Number of Subjects with Return to Within 20% of Baseline WBCT by [CONTACT_184742] 20% 
of Baseline 
15 mg  
(25 mg)  30 mg  
(50 mg)  60 mg  
(100 mg)  120 mg  
(200 mg)  180 mg  
(300 mg)  
10 min  6/10 3/4* 4/6 7/8* 7/8* 
30 min  8/10 4/4 6/7* 7/8* 8/8* 
45 min  6/10 ND 7/7* 8/8* 8/8* 
60 min  4/10 4/4* 7/7* 8/8* 8/8* 
*p<0.05 between ciraparantag and placebo groups.  
ND = No data for time point.  
 
The designated biomarkers in the protocol (PT and TEG-R) were found to be insensitive and too variable for clinical study use.  Whole blood clotting time was identified as the most sensitive and clinically relevant biomarker in a subset of the cohorts and was targeted for use as the primary efficacy variable in all subsequent studies.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 33 of 93 1.2.2 PER977-01-002 
This was a single -blind, placebo-controlled, sequential group, ascending ciraparantag 
dose study in healthy volunteers.  Ten subjects were enrolled in each dose cohort and 
randomized in an 8:2 ratio to ciraparantag: placebo.  All subjects in all cohorts received UFH 5000u by [CONTACT_184743] 5000u administered by [CONTACT_12781] 3 hours (~1667u/hour).   
Six cohorts of 10 subjects had been enrolled and had received 60 mg, 120 mg, 180 mg, 
240 mg, 300 mg, and 360 mg ciraparantag, respectively.  Cohort 4 (240 mg) only was performed as a two -period treatment where each subject received a single dose of 
ciraparantag alone during Period [ADDRESS_435211] comparisons for PoC- aPTT and the 
procoagulant biomarkers TEG-R, D-dimer, F1.2, and TFPI. Across the 60 mg to 360 mg ciraparantag  dose levels, assessments of relationship 
between dosage and reversal of anticoagulation (complete reversal versus partial or 
reversal) and exposure response showed no statistically significant correlations. 
The lack of reversal of unfractionated heparin at the ciraparantag doses utilized in the 
protocol was not unexpected due to the much higher binding ability of unfractionated heparin for ciraparantag compared to the newer oral anticoagulants and the smaller enoxaparin  molecules.  
No deaths, serious adverse events (SAEs), or discontinuations due to AEs were reported. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435212] one TEAE was reported for 35 (72.9%) of the subjects who received ciraparantag 
following UFH:  three subjects (37.5%) who received 60 mg ciraparantag , six subjects 
(75.0%) who received 120 mg ciraparantag, six subjects (75.0%) who received 180 mg ciraparantag, six  subjects (75.0%) who received 240 mg ciraparantag following UFH, six 
subjects (75.0%) who received 300 mg ciraparantag, all eight subjects (100.0%) who received 360 mg ciraparantag and these were all considered related to the study drug by [CONTACT_093]; and seven subjects (87.5%) who received [ADDRESS_435213] one TEAE was reported for two subjects (16.7%) who rece ived placebo 
following UFH – one of them was considered related to the study drug, and one subject  (50.0%) who received placebo without UFH (not related).  
The most common TEAE, feeling hot, was reported for a total of 20 subjects (41.7%) who received cirap arantag following UFH and for two subjects (25.0%) who received 
240 mg ciraparantag without UFH.  All of these events were transient and considered to be mild and related to ciraparantag by [CONTACT_737].  No event of feeling hot was reported for subjec ts who received placebo.  
All TEAEs were considered to be mild in severity by [CONTACT_737]. 
No safety concerns or notable differences were observed in safety laboratory, vital signs, 
pulse oximetry, ECG, telemetry, and fecal occult blood assessments, when comparing active treated cohorts or comparing active treated cohorts and placebo.  
1.2.3 PER977-01-003 
PER977-01-003 was a single-blind, placebo-controlled, sequential group, ascending ciraparantag repeating -dose study in healthy volunteers who received a sing le 
subcutaneous (sc) injection of enoxaparin 1.5 mg/kg.  Four dose cohorts of ciraparantag (60 mg, 120 mg, 180 mg, and 4 x 15 mg ciraparantag, respectively [100 mg, 200 mg, 300 mg and 4 x 25 mg ciraparantag acetate, respectively]) were tested.  In Cohort 1 to 3, additional doses of study drug were allowed in subjects randomized to ciraparantag if PD assessments (WBCT and aPTT) were >120% of baseline value following evaluation of the [ADDRESS_435214] at the pre- study drug time point ≤120% (i.e.≤20% 
increase following enoxaparin) were considered enoxaparin non-responders and were excluded from PD assessments.  
A total of 40 subjects were enrolled (32 to ciraparantag and 8 to placebo) and completed the study.  In Cohorts 1- 3 (ciraparantag 60 mg, 120 mg, and 180 mg [ciraparantag acetate 
100 mg, 200 mg, and 300 mg]) the most commonly AE was flushing, reported in 10 subjects:  2 subjects (25%) who received 60 mg ciraparant ag (100 mg ciraparantag 
acetate), 3 subjects (37.5%) who received 120 mg ciraparantag (200 mg ciraparantag acetate), and 5 subjects (50%) who received 180 mg ciraparantag (300 mg ciraparantag acetate).  Flushing was considered study drug-related in [ADDRESS_435215] (12.5%) who received 
60 mg ciraparantag (100 mg ciraparantag acetate) and in all of the subjects who received 120 mg and 180 mg ciraparantag (200 mg and 300 mg ciraparantag acetate) who reported 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 35 of 93 flushing.  Other TEAEs reported by [CONTACT_350066] (ciraparantag 60 mg [ciraparantag acetate 100 mg]), chills and facial pain (ciraparantag 120 mg [ciraparantag acetate 200 mg]), and chills and dysgeusia (ciraparantag 180 mg [ciraparantag acetate 300 mg ]).   
Table 2: Summary of TEAEs by [CONTACT_184745]   
 60 mg 
(100 mg)  
n=8 120 mg 
(200 mg)  
n=8 180 mg 
(300 mg)  
n=8 15 mg 
(25 mg) 
x 4 
n=8 All Doses  
n=32  Placebo  
n=8 
All related TEAEs, n (%)  2 (25) 4 (50)  7 (87.5)  0 13 (40.6)  0 
General disorders and 
Administration Site Conditions  
 Chills  
 Facial Pain  
 Feeling Hot   
1 (12.5)  
0 
0 
1 (12.5)   
2(25)  
1 (12.5)  
1 (12.5)  
0  
1 (12.5)  
1 (12.5)  
0 
0  
0 0 0 
0  
4 (12.5)  
2 (6.3)  
1 93.1)  
1 (3.1)   
0 0 0 
0 
Nervous System Disorders  
 Dysgeusia  0 
0 0 
0 1 (12.5)  
1 (12.5)  0 
0 1 (3.1)  
1 (3.1)  0 
0 
Respi[INVESTIGATOR_696], Thoracic, and 
Mediastinal Disorders  
 Epi[INVESTIGATOR_184716]   
1 (12.5)  
0 
1 (12.5)   
0 0 
0  
0 0 
0  
0 0 
0  
1 (3.1)  
0 
1 (3.1)   
0 0 
0 
Vascular Disorders  
 Flushing  1 (12.5)  
1 (12.5)  3 (37.5)  
3 (37.5)  5 (62.5)  
5 (62.5)  0 
0 9 (28.1)  
9 (28.1)  0 
0 
 
A total of 30 subjects (75%) were included in the PD population.  Across the three active treatments (ciraparantag 60 mg, 120 mg, and 180 mg [ciraparantag 100 mg, 200 mg, and 300 mg] in Cohorts 1- 3), the mean percent -of-baseline WBCT dropped to ≤120% by 
20 minutes after the end of the ciraparantag injection and remained below 120% for the remainder of the [ADDRESS_435216] (E
max) was consi stently observed 
at [ADDRESS_435217] (E max ) were comparable across the active ciraparantag 
60 mg, 120 mg and 180 mg (ciraparantag acetate 100 mg, 200 mg, and 300 m g) 
treatments (120.77%, 119.57%, and 127.08%, respectively) versus 144.02% in the ciraparantag 15 mg (ciraparantag acetate 25 mg) x 4 dose cohort and 140.63% in the placebo group.  
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 36 of 93 Figure 2:  Percent of Baseline (A -B) WBCT for Al l Treatments  
A.  Percent of Baseline Full Interval  
 
B.  Percent of Baseline Partial Interval (pre -study drug to [ADDRESS_435218] final dose) 
 
*All doses expressed as ciraparantag acetate  

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 37 of 93 Complete reversal (WBCT ≤120% at the 1-hour post study drug administration and 
remaining ≤120% for the 1 to 6- hour interval) was observed in 100% of subjects in 
Cohorts 1, 2, and 3 (60 mg, 120 mg, and 180 mg ciraparantag [100 mg, 200 mg, 300 mg ciraparanta g acetate], respectively), 71.4% in Cohort 4 (ciraparantag 4 x 15 mg [25 mg 
ciraparantag acetate]) and no subject in the placebo group.  Partial reversal (120% to ≤190% at the 1-hour post-study drug administration and for the 1 to 6-hour interval) was observed in 28.6% in Cohort 4 (ciraparantag 4 x 15 mg [25 mg ciraparantag acetate]) and 
100% in the placebo group.  
Statistical assessments comparing ciraparantag treatment versus placebo from all cohorts 
showed no significant differences in F1.[ADDRESS_435219] (E
max), 
minimum effect (E min) or E min from 0 to 6 hours.  Decreases compared to placebo in TFPI 
[INVESTIGATOR_184717] E min (0-6h) were observed with single dose ciraparantag 160 mg to 
180 mg (ciraparantag acetate 100 mg to 300 mg).  There were no significant differences 
between doses in the time to reach minimum effect.  There were no significant changes compared to placebo in any of the secondary pharmacodynamic endpoints following ciraparantag 15 mg (ciraparantag acetate 25 mg) x [ADDRESS_435220] response, was achieved at a single- dose level of 60 mg ciraparantag (100 mg ciraparantag acetate) or 
higher.  Administration of a single-dose of 60 m g ciraparantag (100 mg ciraparantag 
acetate) or above had better reversal of enoxaparin anticoagulation effect than the 15 mg ciraparantag (25 mg ciraparantag acetate) x 4 treatments.  
1.2.4 PER977-02-001 
PER977-02-001 was a randomized single-blind sequential group ascending ciraparantag reversal dose study in healthy volunteers who received a single dose of 60 mg edoxaban in the morning on Days 1-4 followed on Day 3 and Day 4 by a single IV dose of study drug.  Five dose cohorts of 15 mg, 30 mg, 60 mg, 180 mg, and 360 mg ciraparantag (25 mg, 50 mg, 100 mg, 300 mg, and 600 mg ciraparantag acetate), respectively were planned and completed.  Any subject who did not have a minimum increase in WBCT of 25% above baseline at the pre -study drug time point on Day 3 was discontinued from the 
study and replaced.   
The pharmacokinetic results show that following 10- minute IV injection of ciraparantag 
on Day 3 and Day 4, serum PER977 C
max were typi[INVESTIGATOR_184718] 0.25 hour (i.e., at the 
first postdose time point measured five  minutes after the end of the 10- minute injection).  
Ciraparantag was then rapi[INVESTIGATOR_51678], with mean half -life (t 1/2) ranging from 0.207 to 
0.336 hour (12.4 to 20.2 minutes).  Clearance and volumes of distribution remained 
relatively constant across mo st doses and on both Days 3 and 4.  Over the 24-fold dose 
range from 15 mg to 360 mg, ciraparantag C max and total exposures ( AUC (0-inf) and 
AUC (0-last)) increased approximately proportionally to the dose increase.  However, the 
90% confidence interval (CI)  of the slope for Day 4 AUC (0-last) were completely above the 
predefined (0.9298, 1.0702) critical region; and the upper bounds of the 90% CI of the 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435221] time 
point, five minutes after the end of ciraparantag 10-minute injection, and C max was 
reached between 0.42 hour to 0.92 hour after the start of injection.  Elimination of BAP was slower than that of ciraparantag and, the mean t
1/2 of BAP ranged from 0.527 to 1.76 
hours.  Available data on Day 3 suggested an increase in t 1/2 at the 360 mg dose level 
compared to lower ciraparantag doses.  Molar ratios of BAP/ciraparantag exposures ranged from 0.279 to 0.414 for C
max and from 0.538 to 2.49 for total exposures.  With 
ciraparantag administration over the 24-fold dose range, more than proportional increases in serum BAP C
max and total exposures were observed.  The slope estimates  for C max and 
total exposures over the 24- fold dose range were 12% to 48.3% higher than unity and the 
corresponding 90% CIs were completely above the predefined critical region for dose proportionality.   
Urine recovery of ciraparantag dose as unchanged ciraparantag was negligible.  Over the 
12-hour collection interval, the mean overall fraction of dose excreted in urine for analyte over a 12-hour collection (f
e(0-12)) was 0.0377% or less  of administered dose.   
The metabolite BAP was excreted in the urine within the first zero to four hour collection interval in most subjects; and overall, mean f
e(0-12) ranged from 0.886% to 17.7%.  More 
than dose proportional amount of BAP was recovered in the urine.  The mean renal clearance (CL
r) increased with escalating doses, and ranged from 1.38 L/h at the 15 mg 
dose level to 9.02 L/h at the 360 mg dose level.  The mean CL r at the 360 mg dose level 
(9.41 L/h) was comparable to the [ADDRESS_435222] after edoxaban dosing increased to similar levels in the placebo group and ciraparantag treatments.  Over the one to  six hours postdose interval (inclusive) after the 
first ciraparantag dose, complete reversal for WBCT was achieved in a higher percentage of subjects in the active treatments (82.9% for all doses) compared to the placebo group (60.0%).  Across the 30 mg c iraparantag to 360 mg PER977 treatments, the rate of 
complete reversal at 30 mg was slightly lower (62.5%) while the rate was similar for 60 mg or higher dose levels (88.9% to 100%).  Both evaluable subjects (100%) in the [ADDRESS_435223] >190% at any time point (i.e., no 
reversal).  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435224] at pre -study drug on Day 4 versus 
pre-study drug on Day 3.  Over the 1 to 6 hour postdose interval (inclusive) after the 
second ciraparantag dose on Day 4, the rates of complete reversal were comparable to Day 3.  Overall, 88.6% of the subjects in the active ciraparantag treatments and 53.3% of subjects in the placebo group had complete reversal.  Across the 30 mg to 360 mg active treatments, the rate of complete reversal was slightly lower (66.7%) for 180 mg while the rate was similar fo r all other dose levels (87.5% to 100%).  None of the subjects in any of 
the placebo or active treatments had percent -of-baseline WBCT >190% at any time point 
(i.e., no reversal). 
Treatment comparisons of percent-of- baseline WBCT showed lower values compar ed to 
placebo following [ADDRESS_435225] time points between five minutes to three hours after the end of injection (geometric least- squares [LS] ratios ranged from 86.52% to 93.70%); and 
following [ADDRESS_435226] time points between five 
minutes to six hours after the end of injection (geometric LS ratios ranged from 84.91% to 95.71%).  On both study days, WBCT at different dose levels in the active ciraparantag treatments returned to baseline within the 0.083-hour to 0.75-hour time points.  Post- baseline WBCT in placebo -treated subjects did not decrease to baseline level until 
the 1 -hour (Day 4) to 1.5-hour (Day 3) post-study drug time point. 
Secondary evaluation s of ciraparantag effects on whole blood PoC-PT compared to 
placebo were performed for both Day 3 and Day 4.  On both days, none of the subjects in the placebo or ciraparantag treatments had complete reversal.  The rates of partial reversal across all ciraparantag treatments were lower than placebo on Day 3 (25.7% versus 40.0%), and higher than placebo on Day 4 (45.7% versus 26.7%).  There were no statistically significant differences between ciraparantag treatments and placebo for maximum and minimum perce nt-of- baseline PoC -PT (maximum value [E
max], minimum 
value [E min], and E min over the partial six -hour interval post study drug [ciraparantag or 
placebo] [E min(0 -6h)]), except for E max of 100 mg ciraparantag on Day 4 (LS ratio of 
85.19%).  A trend for time to reach minimum value achieved earlier in the ciraparantag treatments compared to placebo was observed; in which the differences were statistically significant for the time of the minimum value ( tE
min) at 360 mg ciraparantag dose level 
on Day 3 (LS difference of -0.7500 h) and tE min at 30  mg PER977 dose level on Day 4 
(LS difference of -3.705 hours).   
For other secondary endpoints, there were no statistically significant differences versus 
placebo in most comparisons for observed and percent-of- baseline values D -dimer, F1.2, 
and TFPI. 
Results of exposure- response assessments showed statistically significant differences for 
tEmin achieved earlier with increasing ciraparantag C max (i.e., negative slopes) on Day 3.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435227] with an AE leading to study discontinuation (due to migraine) was reported 
There was an increase in th e number of subjects who reported at least one 
treatment  emergent AE with an increase in the dose of ciraparantag administered  
No relevant trends were observed over time in the mean and median laboratory values 
between active- treated cohorts and between active -treated cohorts and placebo 
No notable differences were noted in pulse oximetry, ECGs, telemetry, or fecal occult blood assessments, when comparing active treatment groups or comparing active treatment groups and placebo. 
In summary, PER977-02-001 concluded the following: 
• Serum ciraparantag C max and total exposures increased in an approximately 
proportional manner for escalating doses from 15 mg to 360 mg; with no dose 
dependent changes in systemic clearance and volume of distribution. 
• BAP is a major metabolite of ciraparantag that exhibits elimination rate limited 
kinetics.  
• Serum BAP C max and total exposures increased more than proportionally to 
ciraparantag doses over the 15 mg to 360 mg range. 
• Fractions of the ciraparantag dose recovered in the ur ine as BAP and CL r increased 
with escalating doses.  
• Administration of ciraparantag three hours after edoxaban dosing had no apparent impact on the PK of edoxaban and D21-2393. 
• The integrated PD results suggest an anticoagulation reversal effect, as measured by [CONTACT_184736], at 60 mg ciraparantag dose or above. 
• Single -dose administration of ciraparantag had no impact on re- anticoagulation with 
edoxaban. 
• There were no statistically significant differences versus placebo for any of the analytes (D -dimer, F1.2, and TFP I) measured to detect procoagulation signal.  
• Escalating IV doses of ciraparantag (15 mg, 30 mg, 60 mg, 180 mg, and 360 mg) administered three hours after a 60 mg edoxaban administration were considered well 
tolerated in the study population. 
1.2.5 Pharmacokinetics  
In PER977-01- 001, c iraparantag and its primary metabolite, 1,4- Bis(3 -aminopropyl) 
pi[INVESTIGATOR_3746] ( BAP ), demonstrate dose-proportional response both with respect to maximal 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 41 of 93 concentration (C max) and half- life (t ½).  When administered alone, at the lowest dose of 
ciraparantag administered, 3 mg  (5 mg ciraparantag acetate) , the average C max was 
approximately 172 ng/mL ciraparantag in serum and the average t ½ was approximately 
[ADDRESS_435228] ciraparantag dose analyzed, 180 mg (300 mg ciraparantag 
acetate), the average C max was approximately [ZIP_CODE] ng/mL in serum and the average t ½ 
was approximately 17 minutes ( Figure 3). 
Figure 3:  Ciraparantag* Serum Concentration Profile  
 
* All doses expressed as ciraparantag acetate  
BAP reaches T max 20-30 minutes after ciraparantag administration, and C max ranged from 
~ 90 ng BAP/mL serum at a 15 mg ciraparantag (25 mg ciraparantag acetate) dose to 700 
ng BAP/mL serum at a 180 mg ciraparantag ( 300 mg ciraparantag acetate) dose.  
Ciraparantag was found almost exclusively as BAP in  24-hour pooled urine samples 
indicating full metabolism prior to urinary excretion in keepi[INVESTIGATOR_350031] 
14C-PER977 study ( Figure 4 ).  
  

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 42 of 93 Figure 4:  BAP Serum Concentration Profile*  
 
* All doses expressed as ciraparantag acetate  
Ciraparantag  was found almost exclusively as BAP in pooled urine samples ( Figure 5 ) 
indicating full metabolism prior to excretion as was observed in the nonclinical study.  
Figure 5:  Ciraparantag* Urinary Excretion Profile as BAP  
 
* All doses expressed as ciraparantag acetate  
In PER977-01-003, the full 24-hour mean profiles of WBCT generally mirrored 
enoxaparin mean concentration -time profiles, suggesting enoxaparin anticoagulation was 
well reflected by [CONTACT_184736].  The PK of ciraparantag  and its metabolite, BAP , in serum and 
urinary excretion of plasma enoxaparin following administration of 15 mg ciraparantag (25 mg ciraparantag acetate)  x 4 or single doses ranging from 20 mg to 180 mg 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 43 of 93 cirap arantag ( 100 mg to 300 mg ciraparantag acetate) , or placebo (enoxaparin only; 
placebo group) were well characterized.  Administration of ciraparantag four hours after 
enoxaparin did not appear to alter the PK profile of enoxaparin in plasma. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 44 of 93 2 STUDY OBJECTIVES  
The objectives of this Phase 2 study are:  
• To evaluate the efficacy of ciraparantag in the reversal of anticoagulation induced 
by [CONTACT_9674][INVESTIGATOR_3822] 10 mg BID (Q12) at steady state as assessed by [CONTACT_184736]  
• To evaluate the safety and tolerability of ciraparantag 60 mg (100 mg), 120 mg (200 mg), and 30 mg (50 mg), and additional cohorts if necessary approximately 
administered 3 hours after 10 mg api[INVESTIGATOR_350032].  
• To assess the PK characteristics of api[INVESTIGATOR_350033].  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435229] within 3 weeks  prior to check-in, the check-in 
procedures may be modified to exclude redundant procedures at the discretion of the 
Investigator.  There will be a safety review after completion of treatment in one cohort and initiation of treatment in the subsequent cohort. 
Subjects (n=16 per cohort) will be randomized in a 3:1 ratio to receive ciraparantag or 
placebo (saline for injection). Figure 6 depi[INVESTIGATOR_350034] d esign . 
Figure 6:  Study Schema  
 
Throughout the protocol, “study drug” will refer to randomized treatment with ciraparantag or placebo.  T he active study drug doses are expressed as active drug 
substance ( ciraparantag).   
The administered dose is based on a concentration of 6 mg/mL ciraparantag and translates to the following dose conversions:  
Ciraparantag Acetate  Ciraparantag  Dose Volume  
600 mg 360 mg  60 mL  
300 mg 180 mg  30 mL  
100 mg 60 mg 10 mL  
50 mg 30 mg 5 mL  
25 mg 15 mg 2.5 mL  
All subjects will receive 10 mg api[INVESTIGATOR_292928] 3.5 days ( twice daily Q12  on Days 1-3 and 
once on the morning of Day 4).   On Day 4, approximately  [ADDRESS_435230] a minimum increase in clotting time of 20% (as measured by [CONTACT_184736] ) above Day 1 pre -api[INVESTIGATOR_350035]- study 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 46 of 93 drug time point on Day 4 (i.e., 2.[ADDRESS_435231]- api[INVESTIGATOR_3822] ).  Any subject who does not 
have a minimum increase in clotting time of 20% above Day 1 pre -api[INVESTIGATOR_350036] -study drug time point on Day 4 will be discontin ued from the study and 
replaced.  A t approximately  3 hours following api[INVESTIGATOR_3822]  a single IV d ose of study drug 
(ciraparantag or placebo) will be administered.   
Individual subjects may only participate in one dose cohort of this study.  Any subject 
who discontinues prior to completion for reasons other than an AE will be replaced and the replacement subject will receive the same treatment as the original subject.  Subjects who discontinue due to an AE that precedes administration of study drug may be replaced at the discretion of the Sponsor.  Only those subjects who discontinue due to AEs that follow administration of study drug (ciraparantag or placebo) will not be replaced.  
3.2 Dose Rationale 
A total of three dosing cohorts (Cohorts 1-3) are planned.  The planned doses of ciraparantag or placebo (administered as a volume equivalent of ciraparantag ) have been 
evaluated as single and repeat IV doses from  5 mg ciraparantag acetate (3 mg 
ciraparantag) up to 600 mg ciraparantag acetate (360 mg ciraparantag ) in previous 
protocols (PER977-01-001, PER977-01-002, PER977-01-003, and PER977-02-001).  All doses of study drug will be administered by [CONTACT_184746] a minimum of [ADDRESS_435232] participation is approximately 51 days inclusive of screening and follow-up.  Subjects enrolled will spend up to 5 nights admitted to an in -patient facility.
   
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 47 of 93 4 STUDY POPULATION  
4.1 Screening and Enrollment  
The Investigator will maintain a confidential screening log of all potential study 
candidates that includes limited information of the subjects (age, sex), date and outcome of screening process (e.g., enrolled in the study, reason for ineligibility, refused to participate).  
The Investigator will be expected to maintain an Enrollment Log of all subjects enrolled in the study indicating their assigned study number.  
The Investigator will maintain a confidential subject identification code list.  This confidential list of names of all subjects allocated to study numbers upon enrolling in the study, allows the Investi gator to reveal the identity of any subject when necessary.  
Each subject will sign an Informed Consent Form (ICF)  prior to any study assessments.   
Subjects should conform to the inclusion/exclusion criteria for the duration of the study.  If a subject vio lates an inclusion or exclusion criterion at any point during the study, 
he/she may be removed from the study and replaced. 
4.[ADDRESS_435233] of healthy male and female adults, age 50-75 years 
(inclusive).  
No formal sample size calculations were performed for this study; sixteen  (16) subjects 
enrolled in each cohort ( 3:1; active:placebo)  is considered an adequate number of 
subjects to achieve the objectives of the study . 
Estimated number of subjects screened:  120 
Planned number of subjects randomized/dosed:  48 
Planned number of evaluable subjects:  [ADDRESS_435234] meet the following criteria to be enrolled in this study.  
1. Adults age 50 to 75 years, inclusive 
2. Laboratory tests  (chemistry, hematology and coagulation assessments) and 
urinalysis performed during screening up to 36 days prior to administration of 
study treatment deemed  not clinically significant by [CONTACT_62674]. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 48 of 93 3. No clinically significant findings on 12- lead electrocardiogram (ECG) performed 
during screening 
4. Body mass index (BMI) 18 to ≤ 32 kg/m2, inclusive 
5. Male subjects agree to use appropriate contraception (i.e., latex condom with 
spermicide) in addition to their partner using an acceptable form of contraception (e.g., diaphragm, cervical cap, intrauterine device, hormonal contraceptives, surgical sterilization or post-menopausal), when engaging in sexual activity during the course of the study. Moreover, male subjects should not donate sperm or attempt to impregn ate a partner during the course of the study and for a period 
of [ADDRESS_435235] s at screening and check-in 
AND: be surgically sterile at least [ADDRESS_435236] dose  (with 
documentation of hysterectomy, bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], bilateral tubal ligation/tubal occlusion) ; OR post-menopausal (no menstruation for 
a minimum of 12 months and confirmed by [CONTACT_9284] [FSH] of ≥ 40 mIU /ml and serum estradiol < 30 pg/ml) ; OR, if of child-bearing potential, 
must be using an acceptable method of contraception such as an IUD, implant or contraceptive injection, or two  forms of the following (e.g., diaphragm, cervical 
cap, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge) for the last three months .  All females must agree to continue to use their method of 
birth control for the duration of the study and for a minimum of one complete menstrual cycle following discharge fr om the study 
7. Subjects who have participated in a prior study of ciraparantag must have been discharged from the study a minimum of [ADDRESS_435237] be willing to sign the informed consent form indicating voluntary 
consent to participate in the study prior to initiation of screening or study- related 
activities  
4.4 Exclusion Criteria 
Patient s who meet any of the following criteria will be exclude d from the study. 
1. History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal (including gallbladder disease or surgery) , hematologic, or oncologic disease as determined 
by [CONTACT_184739], physical examination, laboratory test results or 12- lead ECG 
assessment.  History or current evidence of liver function tests greater than 50% of the upper limit of normal (ULN) or renal function tests (serum creatinine) greater than 1.5 mg/dl and based on PI [INVESTIGATOR_9106]. History or current evidence of QTc (QTcF) greater than normal ( 450 msec for males or 470 msec for females).  
2. History of unexplained syncope 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 49 of 93 3. History of major bleeding, trauma, or surgical procedure of any type based on PI 
[INVESTIGATOR_9106]  
4. Vaginal  delivery within six months prior to screening  
5. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) within one year prior to screening  
6. Long standing history of bleeding epi[INVESTIGATOR_1865] s such as epi[INVESTIGATOR_3940], bruising or gingival 
bleeding or if not long standing, within [ADDRESS_435238] not undergone hysterectomy, including history of menorrhagia (heavy menstrual bleeding), meno metro rrhagia or polymenorrhea  
9. Smokers or use of tobacco and/or nicotine containing products within [ADDRESS_435239]’s verbal history 
10. Pregnant or breast -feeding  
11. Males with a hi story of hormone therapy within [ADDRESS_435240] or anticoagulant within 3 months prior to study entry or any non- steroidal anti -inflammatory drug or cyclooxygenase 
inhibitor within 2 weeks prior to dosing 
13. Taking any type of chronic medication (including vitamin, nutritional and herbal supplements) for more than 14 consecutive days within the 4 weeks prior to study entry (use of hormonal contraceptives is acceptable except for oral contraceptives )  
14. Positive ser ologic test for human immunodeficiency virus (HIV), Hepatitis C 
virus antibody (HCV- Ab), or Hepatitis B surface antigen (HBsAg)  
15. Donation of blood or blood products within 56 days prior to screening 
16. Participation in any study with an investigational compound or device within 30 days prior to signing informed consent  
17. Active drug or alcohol dependence within the prior 12 months or any condition that, in the opi[INVESTIGATOR_689], would interfere with adherence to study protocol 
18. Allergi c to api[INVESTIGATOR_350037].  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 50 of 93 5 STUDY TREATMENT(S)  
5.1 Description of Treatment(s) 
The following dosage forms will be provided for this study: 
• Ciraparantag for IV injection  
• Placebo for IV injection  
• Api[INVESTIGATOR_3822] 5 mg tablets (commercial formulation  Eliqu is®, [COMPANY_007]/BMS) for oral 
administration  
All doses of study drug (ciraparantag or placebo) will be administered by [CONTACT_51215] 
(over a minimum of 10 minutes) e.g. 60 mg ciraparantag (1 0 ml) will be administered at a 
rate of approximately 1 mL/min and  360 mg  (60 ml ) will be administered at a rate of 
approximately 6  mL/min into an indwelling catheter that is not attached to an IV solution 
and will not result in dilution of the study drug.  The indwelling catheter will be flushed with 5.0 mL of sterile 0.9% Sodium Chloride Injection, USP before and  after 
administration of study drug.  All doses of study drug will be administered in a single -
blinded-fashion. 
5.[ADDRESS_435241] is a sterile, isotonic, pH neutral solution for injection containing 6 mg/mL ci raparantag ( 10 mg/mL ciraparantag acetate)  + 6.4 mg/mL sodium 
chloride to be administered by [CONTACT_51215] ( See the Ciraparantag Investigator Brochure 
for complete description of the chemical structure) . 
5.2.2 Placebo  
Sterile 0.9% Sodium Chloride Injection, USP w ill be administered as the placebo in the 
same method as ciraparantag . 
5.2.3 Api[INVESTIGATOR_350038]  (trade name [CONTACT_350078]
®; [COMPANY_007]/BMS) will be administered  in an 
open-label manner. The ingestion of api[INVESTIGATOR_350039].  
Api[INVESTIGATOR_350040] [ADDRESS_435242], FDA approved dose and is considered safe and well -
tolerated in this population.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435243] 
The doses of ciraparantag utilized in this study were selected based on the cl inical 
findings in PER977-01-001.   
The 10 mg dose for api[INVESTIGATOR_350041] 7 days is recommended for treatment of deep vein 
thrombosis and pulmonary embolism and is a FDA approved dose considered safe and 
well-tolerated in this population. 
All doses of api[INVESTIGATOR_350042] -label manner.  All doses of study 
drugs ( ciraparantag or placebo) will be administered in a single- blind manner (study site 
personnel performing coagulation testing and subjects will be blinded).   
5.4 Method of Assigning Patients to Treatment Groups 
The Investigator will identify all subjects who will meet all inclusion/exclusion criteria 
and who will be enrolled in the study.  Su bjects will be enrolled in cohorts of [ADDRESS_435244] +100 (e.g. if subject [ADDRESS_435245] would be 1101).  
The assignment of treatment will be based on Randomization Schedules to be generated 
by [CONTACT_2024] .  Each cohort will have a different, independently generated randomization 
schedule.  
5.5 Blinding 
This is a single -blind study in which the subjects will be blinded to treatment of the study 
drug (ciraparantag or placebo) and the study personnel assigned to conducting coagulation testing (WBCT) must be blinded as well.  
5.6 Concomitant Therapy 
Use of concomitant medications (including vitamin, nutritional and herbal supplements) is prohibited as per Exclusion criteria, during screening and for the course of the study.  Acetaminophen up to 1 gram/24 hours may be administered for management of AEs at the discretion of the Investigator. As needed use of over-the- counter antihistamines is 
permitted following screening and prior to admission on Day -1 and following discharge from the clinical site on Day 4.   Use of hormonal contraceptives is acceptable except for 
oral contraceptives . 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435246]  2 days before check -in at the clinical s ite for overnight visits. 
When to begin 
diet restriction?  Do not eat and drink  What are some suggested foods that are ok to eat and drink? 
At least 2 days before check -in Any red or rare 
meat. Horseradish, cantaloupe, raw 
turnips, broccoli, 
cauliflower, r ed 
radishes, and 
parsnips. 
NO alcohol (beer, 
wine or liquor) Pasta, rice, potato, dairy, and vegetables 
Non-alcoholic beverages like sparkling cider, 
ginger -ale, Sprite, Crystal- light with no 
caffeine, whole milk (cow, goat, soy)  
 
5.7.[ADDRESS_435247], what times to eat meals and snacks, and when water may be 
consumed. Identical meals will be served for each treatment.  The calorie content, as well 
as the percent of calories from protein, carbohydrate, and fat, will be uniform for each meal during the study (i.e., breakfast uniform to breakfast, lunch uniform to lunch).  Substitutions of food are not allowed.  The calories from fat for the day will not exceed 30% per day.  
5.7.[ADDRESS_435248] or upright position with minimal ambulation (i.e. only to and from the washroom, 
lounge or for study procedures) for the first 8 hours after study drug dosing on Day 4. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 53 of 93 5.8 Treatment Compliance 
All study drug will be administered by [CONTACT_184748] a 
minimum of 10 minutes into an indwelling catheter that is not attached to an IV solution and will not result in dilution of the study drug.  Following administration of the study drug, the indwelling catheter will be flushed with 5.0 mL of sterile 0.9% Sodium Chloride Injection, USP. 
All doses of api[INVESTIGATOR_350043] [ADDRESS_435249] been swallowed. 
5.9 Dose Escalation/De-Escalation 
Review of  WBCT results , AEs, clinical laboratory tests, and ECG data will be conducted 
by a group that includes the Principal Investigator, Medical Monitor(s), and 
representative(s) of the Sponsor.  The group will be responsible for the decision to expand a given dose cohort, es calate (or de- escalate) to a different dose from the planned 
dose, or stop the study. All meetings will be documented with minutes.   
The goal of the study is to explore the dose range of ciraparantag that reverses the 
anticoagulation induced by [CONTACT_350067][INVESTIGATOR_350044]. The study is intended to establish a dose of ciraparantag that fully reverses steady -state api[INVESTIGATOR_3822] , to 
evaluate at least one dose above the reversal dose to establish a therapeutic index, and at least one partial or no  effect dose.  
5.10 Packaging and Labeling 
5.10.1 Ciraparantag  
Ciraparantag Injection will be supplied as a sterile solution for IV injection containing 6 
mg/ml ciraparantag ( 10 mg/mL ciraparantag acetate)  and supplied in 30 clear vials  (5 mL 
each) .  Vials will be labeled for clinical study use including study number, contents, 
quantity, lot number, date of manufacture and stability retest date, and storage conditions 
as well as a caution statement according to 21CFR 312.6(a). 
5.10.2 Api[INVESTIGATOR_350045] 60 tablets  per bottle (NDC 0003-0894-
21).  Bottles will be labeled for clinical study use including study number.   
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435250] be stored in a secure, limited access storage area under the 
recommended storage conditions. 
5.11.1 Ciraparantag  
Ciraparantag will be stored refrigerated at 2 -8°C (36-46°F) and shipped on cold packs to 
the clinical test site.  Temperature will be monitored during shippi[INVESTIGATOR_184721].  
After arrival at the clinical study site, it will be refrigerated at 2 -8°C (36-46°F) until prior 
to administration.  
5.11.[ADDRESS_435251] be stored at 20 -
25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Temperature 
measurements will be recorded.  
5.[ADDRESS_435252] Retention at Study Site 
Investigational study drug will be labeled with the following statement – Caution: New Drug-- Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use. The Principal 
Investigator [INVESTIGATOR_184722], including dates of receipt. In addition, accurate records will be kept regar ding when and how much of each 
test article is dispensed to and used by [CONTACT_184750]. Reasons for deviation from the expected dispensing regimen must also be recorded. A Drug Dispensing Form will be provided for this purpose and wil l be signed by [CONTACT_9532] [INVESTIGATOR_184723]. To satisfy regulatory requirements regarding drug accountability and destruction, following instruction from the Sponsor, the Principal Investigator [INVESTIGATOR_350046], unused, empty and partially 
used study drug and containers to the Sponsor for final accountability and disposal. 
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435253]'s doctor for more information about subject's medical history  
6.[ADDRESS_435254] of the following: 
• General physical well -being will be assessed by [CONTACT_184751], eyes, ears, 
nose, throat, neck, heart, chest, lungs, abdomen, extremities, neurological 
status  (including, but not limited to, consciousness, facial symmetry, 
strength/sensation symmetry, gait), skin, and other conditions of note 
• Measurement of height in street clothes and without shoes (to the nearest  0.5 cm) at 
screening only  
• Measurement of weight in street clothes and without shoes (to the ne arest  0.1 kg). 
Weight will be assessed by [CONTACT_184752] (e.g.,  weight scale). There are 
no adjustments in dose if changes in weight should occur  
• Body mass index is based on height and weight calculated at screening and first 
check -in for eligib ility purposes using the following formula: 
 
BMI =  Weight in kilograms  
Height in meters2 
The abbreviated physical examination will consist of the following:  
• General appearance, heart, lungs, abdomen.  
• Additional physical examinations may be conducted at any time throughout the study, if deemed necessary by [CONTACT_737].  
6.[ADDRESS_435255] is supi[INVESTIGATOR_2525] 5 minutes.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 56 of 93 Vital signs (including blood pressure and pulse [radial or brachial to be measured over 
30 seconds if performed manually]) , respi[INVESTIGATOR_41351], and body temperature ( oral)  will be 
measured at screening . Vital signs will be measured on Day -1, prior to administration of 
api[INVESTIGATOR_350047] [ADDRESS_435256]-study drug. Please see below for tolerance window to perform vital sign assessments:  
Vital Signs Tolerance Window 
Vital Sign  Time  Point Tolerance Window  
Pre-dose -60 minutes to 0 hour  
>0 hour - 4 hour  -10 minutes to +10 minutes  
>4 hour - 12 hour  -20 minutes to +20 minutes  
>12 hour - 24 hour  -30 minutes to +30 minutes  
Study Exit/Early Termination  -30 minutes to +[ADDRESS_435257]’s condition and/or in the following situations: 
• Systolic blood pressure less than 90 mmHg or greater than 180 mmHg  
• Diastolic blood pressure less than 50 mmHg or greater than 100 mmHg 
• Pulse l ess than 40 beats per minute or greater than 110 beats per minute 
• Respi[INVESTIGATOR_71564] 10  breaths per minute or greater than 30 breaths per minute  
• Body temperature less than 36.1°C (97.0°F) or greater than 37.3°C (99.2°F) 
An abnormal vital sign  that is considered clinically significant by [CONTACT_184753].  Additional vital sign measurements may be conducted at 
any time throughout the study, if deemed necessary by [CONTACT_737]. 
6.[ADDRESS_435258]-api[INVESTIGATOR_350016] (±1-hour window) on Day 1 to 4.  PI [INVESTIGATOR_350017]: 
Stroke warning signs: 
• Sudden weakness or numbness of the face, arm or leg, especially on one side 
• Sudden confusion or difficulty understanding 
• Trouble speaking, walking or seeing 
• Dizziness or loss of balance 
• Sudden onset of severe headache 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 57 of 93 Physical symptoms: 
• Facial smiling  or showing of teeth on one side 
• One arm  does not move or drifts compared to the other on extension 
• Abnormal slurred speech, improper choice of words, inability to speak or acute 
confusion and disorientation     
6.[ADDRESS_435259] be negative during check- in 
to continue study participation.  Additional fecal occult blood testing may be conducted at any time throughout the study, if deemed necessary by [CONTACT_737].  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 58 of 93 6.6.2 Laboratory Parameters  
Values for the c linical laboratory tests listed below will be determined by [CONTACT_350068](ies).   
CLINICAL CHEMISTRY  HEMATOLOGY  
The following clinical chemistry tests will be 
performed at screening, check -in, and discharge 
from the study:  The following hematology tests will be performed 
at screening, check- in, and discharge from the 
study:  
Alanine aminotransferase (ALT)  Hematocrit  
Albumin  (ALB)  Hemoglobin  
Aspartate aminotransferase (AST)  Platelet count  
Blood urea nitrogen (BUN)  RBC  
Calcium  WBC / with differential  
Chloride   
CO 2 COAGULATION  
Creatinine (CR)  The following coagulation tests will be performed 
at screening, check- in, and discharge from the 
study:  Direct bilirubin (DBIL)  
Glucose  
Indirect bilirubin (IBIL)  PT-PTT 
Lactose dehydrogenase (LDH)   
Magnesium  URINALYSIS  
Potassium  The following urinalysis tests will be performed 
at screening, check- in, and discharge from the 
study:  Sodium  
Total bilirubin (TBIL)  Appearance  
Total Protein  Bilirubin  
 Blood  
 Color  
FECAL OCCULT BLOOD TEST  Glucose  
Fecal occult blood test (conducted at clinical site  
at check -in) Ketones  
Microscopic examination  
 pH 
 Protein  
PREGNANCY SCREEN** (females only)   Specific gravity  
Urine pregnancy test s will be performed at 
screening  and at discharge.  Serum pregnancy test 
will be done at check -in on Day - [ADDRESS_435260] -
menopausal females  at screening and check- in on 
Day -1 
**the urine pregnancy tests may be performed in -
clinic using CLIA -waived marketed kits.   
OTHER TEST:  
Urine Random Creatinine  test will be 
performed at screening, check -in, and discharge 
from the study  
Saliva Alcohol Test  
(to be performed at screening and at check -in 
using CLIA –waived marketed kits)  VIRAL SCREEN*** (to be performed at 
screening only):  
Urine Drug Screen   
(to be performed at screening and check -in using 
CLIA –waived marketed kits)  HBsAg  
HCV antibody test  
HIV antibody test  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 59 of 93 6.6.3 Experimental Safety Biomarker Assessment  
Two aliquots of c itrated plasma  (1 ml each) for e xperimental safety biomarker 
assessment s (e.g. D -Dimer, F1.2 tests) will be collected at pre -api[INVESTIGATOR_3822] (within 1 hr. 
prior to dosing) on Day 1, and at 2.[ADDRESS_435261]- api[INVESTIGATOR_292981] 4. Experimental 
safety biomarker  assessment will only be performed at the discretion of the Principal 
Investigator. 
6.7 Electrocardiograms 
A resting 12- lead electrocardiogram will be performed at screening,  check -in, after 
administration of api[INVESTIGATOR_3822] , and prior to discharge from the clinic site.  Parameters 
assessed will include ventricular rate (bpm), PR interval (msec), QRS duration (msec), 
QT interval (msec) and QTc interval (msec). Additional ECGs may be performed  at the 
discretion of the Principal Investigator.  
6.[ADDRESS_435262] 1 hour before administration.  The appropriate volume of 
Ciraparantag  Injection will be withdrawn from the supplied vials. 
Throughout this protocol, the active study drug doses are expressed as active drug substance (ciraparantag)  (previously study drug doses were expressed as ciraparantag 
acetate with a content of 10 mg/mL ).  The administered dose is based on a concentration 
of 6 mg/mL ciraparantag and translates to the following dose conversions:  
Ciraparantag Acetate  Ciraparantag  Dose Volume  
[ADDRESS_435263] be labeled with the study number and date. 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435264] an expi[INVESTIGATOR_19860] 4 hours 
at room temperature or will be refrigerated at 2 -8°C (36-46°F) until use.  All prepared 
solutions must be used within [ADDRESS_435265] be kept of all discarded solutions.  
6.8.2 Placebo  
An equivalent volume of sterile 0.9% Sodium Chloride Injection, USP will be utilized as 
the placebo.   
All placebo doses must be labeled with the study number and date.  Placebo  may be prepared on the day of dosing and will have an expi[INVESTIGATOR_19860] 4 hours at 
room temperature or will be refrigerated at 2 -8°C (36-46°F) until use.  All prepared 
solutions must be used within [ADDRESS_435266] number and date.  All unused tablets will be returned to the pharmacy.   
6.9 Efficacy Assessments 
Time 0 for all PK and PD assessments will be the end of the study drug injection.  Where 
timing for assessments coincide, PD assessment(s)  should be performed first, followed by 
[CONTACT_184733](s) , and then ECGs, and vital signs will be performed. The tolerance 
window to complete PK and PD draws is as follow: 
PK/P D Draw Tolerance Window  
Sampling Time  Point Tolerance Window  
Pre-dose -60 minutes to 0 hour  
>0 hour - 24 hour -10 minutes to + [ADDRESS_435267] for the combined PK, PD and safety evaluations is approximately 175 mL.  
6.9.1 Pharmacokinetic Assessment  
Blood samples for PK assessment of ciraparantag  and its metabolite , and api[INVESTIGATOR_3822] , will 
be analyzed using LC/MS assay methodology. 
Api[INVESTIGATOR_350023]: 
A 4 mL blood sample in potassium EDTA will be collected for each PK assessment of api[INVESTIGATOR_3822] .  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 61 of 93 Day 1: pre -api[INVESTIGATOR_3822] (within 1 hr. prior to dosing) 
Day 4: post- api[INVESTIGATOR_350024] 2.[ADDRESS_435268]- study drug at 15, 30, 45 minutes, and 1, 3, 5, 
24 hrs.  
Ciraparantag and  BAP  PK time points:  
Ciraparantag or placebo is administered 3 hrs. after the api[INVESTIGATOR_350048] D ay 4. 
A 3 mL blood sample with no additive (i.e. serum  sample) will be collected for each 
PK assessment of ciraparantag and its metabolite.  
Day 4: pre-study drug (within 1 hr. prior to dosing of ciraparantag or placebo) and  
post-study drug at 15, 30, 45 minutes, and 1, 3, 5, 24 hrs. 
6.9.2 Pharmacodynamic Assessment  
Blood samples (2 ml) for measuring of clotting time by [CONTACT_350069]: 
Day 1: pre -api[INVESTIGATOR_350025] (within 1 hr. prior to dosing) 
Day 4: post- api[INVESTIGATOR_350024] 2.[ADDRESS_435269]-study drug at 15, 30, 45 minutes, and 1, 3, 5, 
24 hrs. (only subjects with at least 20% increase of clotting time from the Day 1 pre -
api[INVESTIGATOR_350026]). 
Triplicate WBCT will be done Day [ADDRESS_435270]-study drug at 1 hr on Day 4. 
6.10 Adverse Events Assessments 
All AEs and SAEs will be captured by [CONTACT_208002] (E DC).  
All AEs occurring after the subject signs the ICF up to the time of the Follow -up phone 
call, whether observed by [CONTACT_19007], will be captured. If 
in the opi[INVESTIGATOR_350049], an AE meets the criteria of an SAE it is 
to be reported. SAEs  occurring up to [ADDRESS_435271].  Medical conditions (including laboratory values/vital signs that are out of range) that were diagnosed or known to exist prior to Informed Consent will be recorded as part of medical history.  All SAEs are to be reported according to the procedures in Section 6.10.10 SAE Reporting- Procedure for 
Investigators.  Report diagnosis as the AE or SAE term; when the diagnosis is unavailable, report signs and symptoms as individual entries of AE or SAE until the 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435272] be reported as the serious adverse event (diagnosis or symptom requiring hospi[INVESTIGATOR_059]).  A procedure is not an AE or SAE, but the reason for the procedure may be an AE or SAE.  Pre-planned (prior to signing the Informed Consent Form) procedure or treatment requiring hospi[INVESTIGATOR_5912]-existing conditions which do not worsen in severity should not be reported as SAEs.  For deaths, the underlying or immediate cause of death should always be reported as an SAE.  In addition, any serious, untoward event that may occur subsequent to the reporting period that the Investigator assesses as related to study drug should also be reported and managed as an SAE. 
At each visit, the Investigator will determine whether any AEs have occurred by 
[CONTACT_194761].  Adverse events may be directly observed, reported spontaneously by [CONTACT_350070].  Subjects should be questioned in a general way, without asking about the occurrence of any specific symptoms.  All abnormal laboratory values must be appraised by [CONTACT_350071].  All abnormal laboratory values considered clinically significant by [CONTACT_184758], and if serious, reported as an SAE  following the procedures in Section 6.10.10. 
Investigator should follow subjects with AEs until the event has resolved or the condition has stabilized.  In case of unresolved AEs including significant abnormal laboratory values at the end of study assessment, these events will be followed until resolution or until they become clinically not relevant.  
6.10.1 Clinical Laboratory Abnormalities and Other Abnorm al Assessments as 
Adverse Events or Serious Adverse Events 
Laboratory abnormalities are usually not recorded as AEs or SAEs.  However, laboratory abnormalities (e.g., clinical chemistry, hematology, and urinalysis) that require medical or surgical interven tion or lead to study drug discontinuation must be recorded as an AE, 
as well as an SAE, if applicable.  In addition, laboratory or other abnormal assessments (e.g., ECG or vital signs) that are associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE (or SAE) as described in 
Section 6.10.3 and Section 6.10.4, respectively.  For AEs associated with laboratory abnormalities, the event should be graded on the basis of the clinical severity in the context of the underlying conditions; this may or may not be in agreement with the grading of the laboratory abnormality. 
6.10.[ADDRESS_435273] safety will be monitored closely. All clinically significant treatment -emergent 
AEs (TEAEs)  denoted by [CONTACT_350072] t he 
Perosphere medical monitor. All subjects experiencing a TEAE must be monitored 
periodically until symptoms subside or until there is a satisfactory explanation for the AE.  Additionally, treatment-emergent abnormal laboratory values should be monitored 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 63 of 93 periodically until the abnormality resolves, returns to baseline levels, or is otherwise 
explained.  A t the discretion  of the Investigator, a ssessments a nd/or  clinic v isits in 
addition to those scheduled for routine study conduct may be wa
rranted to proper ly 
monitor the AE or laboratory abnormality. T o ensure subject safety, the Investigator may 
as
k the  subject to s ign a medical release f orm allow ing him to c ontact the  subject's do ctor 
for more inform
ation about subjec
t's medical history.  All questions regarding toxicity 
management should be directed to the Perosphere medical monitor. 
6.10.3  Adverse Event  (AE) 
An A E is any unt oward medical o ccurrence in a subject  or clinical i nvestigat ion s ubject 
administered a pharmaceutical product and whic h does not necessarily have  to have a 
causal relationship with t
his tr
eatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom , or 
disease temporally associated with the use of a medicinal product, whether or not 
considered related to  the medicinal product (ICH E2A Guideline, C linical Safety Data 
Management: Definitions and Standards for Expedited Reporting, Oct 1994) . 
It is the res
ponsibility of Investigator
s, based on their know ledge and experience, to 
determine, those circumstances or abnormal lab findings which should be considered 
adverse events. 
6.10.4  Serious Adverse Event (SAE) 
Any unt oward m edical oc currence that at an y dose: 
•Results in death,
•Is life -threatening,
•Requires inpatient hospi[INVESTIGATOR_1081],
•Results in persistent or significant disability/incapacity,
•Is a congenital anomaly/birth defect, or
•Is an imp ortant medical event
Note: The  term “life -threatening” in the definition of “serious” refers to an event in which 
the subject was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe (ICH E2A Guideline, 
Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, 
Oct 1994) . 
Medical and scientific judgment should be exer
cised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be imme diately lif e-threatening or result in deat h or hospi[INVESTIGATOR_350050]
e intervention to prevent one of the other outcomes listed in the 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435274] ug abuse.  
6.10.5 AE Severity  
The following definitions should be used to assess intensity of adverse events: 
Mild: Awareness of sign or symptom, but easily tolerated, i.e., does not interfere with subject’s usual function. 
Moderate: Discomfort enough to cause int erference with usual activity.  
Severe: Incapacitating with inability to work or do usual activity, i.e., interferes 
significantly with subject’s usual function. 
Severity should be distinguished from seriousness. Severity is a measure of intensity whereas seriousness is classified by [CONTACT_184760]. An AE of severe intensity need not necessarily be classified as serious.  
6.10.6 Causality Assessment  
The Investigator should assess causal relationship between an AE and ciraparantag  and/or 
api[INVESTIGATOR_3822]  (if administered) on the basis or his/her clinical judgment and the following 
definitions.  The causality assessment should be made based on the available information and can be updated as new information becomes available. 
1 = Related:  
The AE follows a reasonable temporal sequence from study drug administration, and 
cannot be reasonably explained by [CONTACT_423]’s clinical state or other factors (e.g., 
disease under study, concurrent diseases, and concomitant medications). 
The AE follows a reasonable temporal sequence from study drug administration, and 
is a known reaction to the drug under study or its chemical group, or is predicted by 
[CONTACT_25046]. 
2 = Not Related:  
The AE does not follow a reasonable sequence from study product administration, or can be reasonably explained by [CONTACT_423]’s clinical state or other factors (e.g., disease under study, concurrent diseases, and concomitant medications). 
6.10.7 Action Taken Regarding the Study Drug  
The following definitions will be used to describe action taken regarding study drug: 
1 = Dose Not Changed: No change in study drug dosage was made. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 65 of 93 2 = Drug Withdrawn: The study product was permanently stopped. 
3 = Dose Reduced: The dosage of study product was reduced. 4 = Drug Interrupted: The study product was temporarily stopped. 5 =Dose Increased: The dosage of study product was increased. 
6.10.8 Adverse Event Outcome 
The following definitions will be used to describe AE outcomes: 
1 = Recovered/Resolved  
The subject fully recovered from the AE with no resi dual effect observed.  
2 = Recovered/Resolved with Sequelae 
The residual effects of the AE are still present and observable.  
Include sequelae/residual effects.  
3 = Not Recovered/Not Resolved 
The AE itself is still present and observable.  
4 = Fatal  
5 = Unknown  
6.10.9 Other Action Taken for Event 
The following definitions will be used to describe other actions taken for an AE:  
1 = None. 
No treatment was required.  
2 = Medication required. 
Prescription and/or OTC medication was required to treat the adverse event. 
3 = Hospi[INVESTIGATOR_46823]. 
Hospi[INVESTIGATOR_184728], whether or 
not medication was required. 
4 = Other.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 66 of 93 6.10.10 Serious Adverse Event Reporting –Procedure f or Investigators  
[IP_ADDRESS]  Initial Reports  
Within [ADDRESS_435275] 
Perosphere as notification of an SAE and report the SAE via EDC, facsimile or email to: 
AMAG Pharmacovigilance  
Email:  
Fax:  
SAE queries should be addressed as soon as possible. 
[IP_ADDRESS]  Follow-up Reports 
The Investigator will follow all SAEs  until the SAE is: 
●Resolved, or
●Stabilized ( e.g., in the case of persistent impairment), or
●Returned to baseline, if a Baseline value is available,  or
●Otherwise justified by [CONTACT_350073]
●All relevant data are received
If NEW information become available on a previously reported SAE, within [ADDRESS_435276] the sponsor with a follow -up report: 
•Report the updated information on the SAE via facsimile as listed above
•For SAEs that resulted in death, provide the autopsy report, if done, via e-mail, fax, or
express mail to Perosphere
•Perosphere  will review the follow up SAE information and supporting documents and
issue additional queries as needed
6.10.11 Notifying Regulatory Authorities, Investigators, and IRB /IEC  
Perosphere will report any Suspected Unexpected Serious Adverse Event Reactions 
(S[LOCATION_003]Rs) for ciraparantag  and api[INVESTIGATOR_350051] (IND) and Investigational Medicinal Product Dossier (IMPD) (if applicable) .  Serious unexpected serious adverse 
reactions (S[LOCATION_003]Rs) attributed to both ciraparantag  and api[INVESTIGATOR_350052].  Perosphere is  responsible for submission of ciraparantag  and api[INVESTIGATOR_350053], respectively, if applicable.  Perosphere will notify participating Investigators and IRB /IEC  of all SUS ARs ( ciraparantag  and/or api[INVESTIGATOR_3822] ) occurring in 
this study or other ciraparantag  studies. 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435277] well- baby [CONTACT_184761]-Up Report Form. All reports of congenital abnormalities/birth defects and spontaneous abortions/miscarriages should be reported as an SAE for the study.  
Elective aborti on procedures, without complications, will not be considered as AEs. 
6.[ADDRESS_435278] their study treatment discontinuation recorded. 
Subjects may be withdrawn from the study after signing informed consent for the 
following reasons: 

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 68 of 93 • Adverse Event  
• Lost to Follow-up 
• Withdrawal of Consent by [CONTACT_27720] 
• Investigator decision 
• Death  
• Pregnancy  
• Study terminated by [CONTACT_2728]  
• Other (any othe r reason)  
If a subject withdraws from the study, the Investigator will complete and report the 
observations as thoroughly as possible up to the date of withdrawal including the date of last treatment and the reason for withdrawal.  
If the subject is withdrawn due to an AE, the Investigator will follow the subject until the AE has resolved or stabilized. 
All subjects who are withdrawn from the study should complete protocol specified 
withdrawal procedures . 
6.12.[ADDRESS_435279] may be withdrawn from the study at the discretion of the Investigator or Sponsor, if judged non-compliant with study procedures or due to safety concerns.  These criteria include: 
• Unwillingnes s to continue with the study, or because of unwanted effects due to study 
drug  
• Ingestion of interfering substances at times other than those specified in the protocol 
during the course of the study or,  
• Intercurrent illness or concomitant medication that, in the Investigator’s judgment, may interfere with the conduct of the study. 
• Study drug will be administered only to those subjects who have a minimum increas e 
in WBCT of 20% from Day 1 pre -api[INVESTIGATOR_350054]- study drug (i.e., 
2.[ADDRESS_435280]- api[INVESTIGATOR_3822] ) time point on Day 4.  Any subject who does not have a 
minimum increase in WBCT  of 20% from Day 1 pre-api[INVESTIGATOR_350055]-study drug time point on Day 4 will be discontinued from the study and replaced.  
Subjects who withdraw from the study prior to completion will undergo abbreviated 
physical exam, vital signs, ECG, and safety laboratories prior to release from the  study 
center.  An additional 2 mL blood sample will be collected for confirmatory coagulation 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 69 of 93 testing  (WBCT ).  All subjects who discontinue from the study prior to completion will 
receive a telephone call as follow -up for AEs 3- [ADDRESS_435281].  Subjects who 
discontinue due to an AE that precedes administration of study drug may be replaced at the discretion of the Sponsor .  Only those subjects who discontinue due to AEs that 
follow administration of study drug ( ciraparantag  or placebo) wi ll not be replaced.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435282], 
followed by [CONTACT_184733](s) as indicated, and then safety measurements .   
Time [ADDRESS_435283]-study drug procedures will be the end of the 
study drug injection. 
7.1 Screening Visit (Days -36 to -1) 
The following activities and/or assessments will be performed at/during Screening in all 
cohorts: 
• Written Informed Consent 
• Review of Inclusion/Exclusion criteria 
• Recording of demographic data, medical/surgical history, medication history  
• Vital signs, ECG, and safety laboratory tests  (hematology, chemistry , coagulation and 
urinalysis) 
• Complete physical examination  
• Height and weight measurement, and BMI calculation  
• Blood draw for HIV, HBsAg, HCV -Ab 
• Urine  pregnancy test for all female subjects  
• FSH and Estradiol tests for post- menopausal female subjects  
• Saliva alcohol test  and urine drug screen 
• Each subject will be giv en an occult blood kit to be returned at the check- in  
• Subjects will be provided with a lifestyle and dietary guide 
• Adverse events and c oncomitant medi cations will be recorded  
7.2 Treatment Period (Day -1 to Day 5) 
7.2.1 Check -in (Day -1) Procedures  
The following activities and/or assessments will be performed on Day - 1 in all subjects: 
• Check -in to the clinical site  
• Review of Inclusion/Exclusion criteria 
• An ECG , vital signs, and safety laboratory tests  (hematology, chemistry , coagulation  
and urinalysis) 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 71 of 93 • Weight and BMI calculation  
• Saliva alcohol and  urine drug screen  
• Serum pregnancy test s in all female subjects  
• FSH and e stradiol tests for post- menopausal female subjects  
• Fecal occult blood analysis  
• In the event the occult blood kit is not returned, a rectal exam for stool sample may be 
performed at the discretion of the Investigator.  
• Abbreviated  physical examination   
• AEs and c oncomitant medications will be recorded  
• If the screening visit for the subject is within 3 week s of check -in, redundant 
procedures (ECG, safety laboratory tests, and physical examination) may be omitted 
at the discretion of the PI. 
7.2.2 Day 1 Procedures  
The following activities and/or assessments will be performed on Day 1 in all subjects: 
• Administratio n of 10 mg dose of api[INVESTIGATOR_292901] (Q12) after meal ; Maintain fast for 4 
hours after the api[INVESTIGATOR_157286]; water allowed ad libitum  
• An ECG  
• Vital signs prior to api[INVESTIGATOR_350056] 
• Blood draw for experimental safety biomarker assessment and Day [ADDRESS_435284]  
prior to api[INVESTIGATOR_292947] 
• AEs and c oncomitant medications will be recorded  
• Stroke assessm ent at approximately [ADDRESS_435285]-api[INVESTIGATOR_350016] (±1-
hour window)  
7.2.3 Day 2 and Day 3 Procedures  
The following activities and/or assessments will be performed on Day 2  and 3 in all 
subjects:  
• An ECG   
• Vital signs  prior to api[INVESTIGATOR_350056] 
• Administration of 10 mg dose of api[INVESTIGATOR_292901] (Q12) after meal ; Maintain fast for 4 
hours after the api[INVESTIGATOR_157286] ; water allowed ad l ibitum  
• AEs and c oncomitant medications will be recorded  
• Stroke assessment  at approximately [ADDRESS_435286]-api[INVESTIGATOR_350016] (±1-
hour window)  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 72 of 93 7.2.4 Day 4 Procedures  
[IP_ADDRESS]  Pre-study drug 
The following activities and/or assessments will be performed on Day 4 before 
administration of study drug in all subjects: 
• Administration of a single [ADDRESS_435287]; Maintain fast for 4 
hours after the api[INVESTIGATOR_157286]; Water allowed ad libitum  
• An ECG and vital signs  
• Blood draw for PK assessment of api[INVESTIGATOR_350057] 2.[ADDRESS_435288]- api[INVESTIGATOR_3822]  
• Blood draw for WBC T measurement (triplicates  post- api[INVESTIGATOR_350058] 2.75 hrs.) 
• Blood draw for experimental safety biomarker assessment 
• Randomization 
• AEs and c oncomitant medications will be recorded  
• Stroke assessment at approximately [ADDRESS_435289]-api[INVESTIGATOR_350016] (±1-
hour window)  
[IP_ADDRESS]  Study Drug  Administration: Time 0  
The following activities and/or assessments will be performed  in the order listed on Day 
4 in all subjects: 
• Vital signs  prior t o study drug 
• I.V. a dministration of study drug (ciraparantag or placebo)  
• AEs and concomita nt medications will be recorded  
[IP_ADDRESS]  Post-study Drug: 15 minutes 
The following activities and/or assessments will be performed on Day [ADDRESS_435290] administration of study drug in all subjects: 
• Blood draw for WBCT  
• Blood draw for PK samples for ciraparantag/metabolite and api[INVESTIGATOR_3822]   
• AEs and c oncomitant medications will be recorded  
• Post- study Drug: 30 minutes  
The following activities and/or assessments will be performed on Day [ADDRESS_435291] administration of study drug in all subjects: 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 73 of 93 • Blood draw f or WBCT  
• Blood draw for PK samples for ciraparantag/metabolite and api[INVESTIGATOR_3822]  
• AEs and concomitant medications will be recorded  
[IP_ADDRESS]  Post-study Drug: 45 minutes 
The following activities and/or assessments will be performed on Day [ADDRESS_435292] administration of study drug in all subjects: 
• Blood draw for WBCT  
• Blood draw for PK samples for ciraparantag/metabolite a nd api[INVESTIGATOR_3822]  
• AEs and concomitant medica tions will be recorded  
[IP_ADDRESS]  Post-study Drug: 1 hour 
The following activities and/or assessments will be performed on Day [ADDRESS_435293] 
administration of study drug in all subjects: 
• Blood draw for WB CT (triplicates)  
• Blood draw for PK sample s for ciraparantag /metabolite  and api[INVESTIGATOR_3822]  
• AEs and concomita nt medications will be recorded  
[IP_ADDRESS]  Post-study Drug: 1.5 hour  
• Vital signs  
[IP_ADDRESS]  Post-study Drug: 3 hours 
The following activities and/or assessments will be performed on Day [ADDRESS_435294] 
administration of study drug in all subjects: 
• Blood dra w for WBCT  
• Blood draw for PK sample s for ciraparantag /metabolite  and api[INVESTIGATOR_3822]  
• AEs and c oncomitant medications will be recorded  
[IP_ADDRESS]  Post-study Drug: 4 hours  
• Vital signs  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 74 of 93 [IP_ADDRESS]  Post-study Drug: 5 hours 
The following activities and/or assessments will be performed on Day [ADDRESS_435295] 
administration of study drug in all subjects: 
• Blood draw for WBCT  
• Blood draw for PK sample s for ciraparanta g/metabolite and api[INVESTIGATOR_3822]  
• Blood draw for experimental safety biomarker assessment  
• AEs and concomitant medications will be recorded  
[IP_ADDRESS]  Post-study Drug: 8 hours  
• Vital sign s 
[IP_ADDRESS]  Post-study Drug: 24 hours 
The following activities and/or assessments will be performed on Day [ADDRESS_435296] 
administration of study drug in all subjects: 
• Blood draw for WBC T 
• Blood draw for PK sample s for ciraparantag /metabolite  and api[INVESTIGATOR_3822]  
• Vital signs  
• AEs and concomitant m edications will be recorded  
7.2.5 Day 5 or Early Termination  Procedures  
The following activities and/or assessments will be performed on Day 5 prior to discharge in all subjects:  
• An ECG  and safety laboratory tests (hematology, chemistry and urinalysis) 
• Vital signs  (the vital sign assessment at [ADDRESS_435297]-study drug may be use d for 
discharge)  
• Urine pregnancy test for female  
• AEs and concomitant medications will be recorded  
• Abbreviated physical examination  
• Discharge fro m the clinical site if coagulation parameter ( WBCT ) are not clinically 
significant.  If there is an abnormal la boratory test result or AE, the subject may need 
to return for repeat testing.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 75 of 93 7.3 Follow-up (Day 7-10) 
The following activities and/or assessments will be performed during the follow -up in all 
subjects:  
• Telephone follow-up  
• AEs and concomitant medications w ill be recorded  
• Discharge from the study  
Subjects may be asked to return to the clinical site at the discretion of the Investigator.  
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 76 of 93 8 QUALITY CONTROL AND ASSURANCE  
The Investigator/investigational site will permit study -related monitoring, audits, 
IRB/IEC review and regulatory inspections by [CONTACT_169293]/documents.  Direct access includes permission to examine, analyze, verify, and 
reproduce any records and reports that are important to the evaluation of a clinical study. 
8.[ADDRESS_435298], inspecting the various records of the study (e.g., case report forms, source data, and other pertinent documents). 
The monitor is responsible for visiting site(s) at regular intervals throughout the study to 
verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to ICH/GCP and local regulations on the conduct of clinical research.  The monitor is responsible for inspecting the case report forms and ensuring completeness of the study essential documents.  The monitor should have access to subject medical records and other study- related records needed to verify the entries on the case report 
forms.  
The monitor will communicate deviations from the protocol, Standard Operating Procedures (SOPs), GCP and applicable regulations to the Investigator and the Sponsor and will ensure that appropriate action designed to prevent recurrence of the detected deviations is taken and documented. 
The Investigator agrees to cooperate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are addressed and documented. 
In accordance with ICH/GCP and the Sponsor’s audit plans, this study may be selected 
for audit by [CONTACT_184762].  Inspection of site facilities (e.g., pharmacy, drug storage areas, laboratories etc.) and review of study related records will occur in 
order to evaluate the study conduct and compliance with the protocol, ICH/GCP, and 
applicable regulatory requirements.  
In the event Perosphere elects to conduct an audit onsite, the CRO  will be notified in 
advance, will be given sufficient time to prepare, and will be given an opportunity to participate in the audit.  
8.2 Data Collection 
Case Report Form (CRF) completion should be kept current to enable the monitor to review the subject’s status throughout the course of the study.  Case Report Form will be completed, reviewed and signed off or e- signed by [CONTACT_737].  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435299] will be ongoing.  
The Principal Investigator [INVESTIGATOR_184729]: 
1. Monitoring study conduct to ensure that the rights of subjects are protected; 
2. Monitoring study conduct to ensure trial compliance with GCP guidelines; and 
3. Monitoring accuracy, completion and verification from source documents of 
study data.  
8.[ADDRESS_435300] of appropriately qualified persons to 
whom he/she has delegated study duties.  All persons authorized to make entries and/or corrections on case report forms will be included on the Signature [CONTACT_46979]. 
Source documents are original documents, data, and records from which the subject’s 
case report form data are obtained.  These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and pharmacy  records, diaries, microfiches, X- rays, 
and correspondence. 
Case Report Form entries may be considered source data if the CRF is the site of the 
original recording (i.e., there is no other written or electronic record of data).  In this study, CRF pages may be used as source documents. 
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system (Trial Master File  [TMF] ) of all study -related (essential) 
documentation, suitable for inspection at any time by r epresentatives from Perosphere 
and/or applicable regulatory authorities.  Essential documents include: 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 78 of 93 • Subject files containing completed CRFs, ICFs, and supporting copi[INVESTIGATOR_31653] (if kept) 
• Study files containing the protocol with all amend ments, Investigator’s Brochure, 
copi[INVESTIGATOR_46828] a clinical study, 
and all correspondence to and from the IRB /IEC  and Perosphere. 
• Records related to the Investigational Product(s) including acknowledgment of 
receipt at site, accountability records and final reconciliation and applicable 
correspondence 
• In addition, all original source documents supporting entries in the case report forms 
must be maintained and be readily available.  
8.[ADDRESS_435301], regulatory documents (e.g., protocol and amendments, IRB/EC correspondence and approvals, approved and signed informed consent forms, Investigator’s Agreement, clinical supplies receipts, distribution and return records), and other sponsor correspondence pertaining to the study must be kept in appropriate study files at the site.  Source documents include all recordings and observations or notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical study.  These records will be retained in a secure file for the period required by [CONTACT_175230].  Prior to transfer or destruction of these records Perosphere must be notified in writing and be given the opportunity to further store such records. 
8.[ADDRESS_435302].  These documents should be retained for a longer period, however, if required by [CONTACT_70469].  It is the responsibility of the sponsor to inform the Investigator/institution as to when these documents no longer need to be retained. 
No study document should be destroyed without prior written agreement between 
Perosphere and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify Perosphere in writing of the new responsible person and/or the new location. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 79 of 93 9 PLANNED STATISTICAL METHODS  
9.1 General Considerations 
All data collected will be presented in data listings.  Data from subjects excluded from an 
analysis set will be  presented in the data listings, but not included in the calculation of 
summary statistics.  For categorical variables, frequencies, and percentages will be presented.  Continuous variables will be summarized using descriptive statistics (number of subjects, mean, median, standard deviation, minimum, and maximum).  Data will be tabulated by [CONTACT_3148], across active treatment groups when applicable, with all placebo subjects pooled into a single group. 
All evaluable data from subjects in the analysis sets wi ll be included in the analyses.  No 
adjustment or imputation will be utilized for missing values or for subjects who withdraw 
prior to completing the study, neither will analyses be restricted to subjects with complete data.  
Baseline values will be defined  as the last assessment prior to investigational product 
administration and per period if applicable. 
Details of all statistical analys es will be specified in a separate statistical analysis plan 
(SAP)  that will be finalized prior to database lock . 
9.[ADDRESS_435303] of healthy male and female adults, age 50-75 years 
(inclusive).  No formal sample size calculations were performed for this study; sixteen  (16) subjects 
enrolled in each cohort (3:1; active: pl acebo)  is considered an adequate number of 
subjects to achieve the objectives of the study . 
Estimated number of subjects screened:  120 
Planned number of subjects randomized/dosed:  48 
Planned number of evaluable subjects:  [ADDRESS_435304] these measurements. This set will be used for all PD analyses.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435305] these measurements. This set will be used for 
all PK analyses.  
9.4 Pharmacokinetics of PER977 and Metabolite (BAP) 
PER977 and BAP serum concentration values will be summarized in terms of arithmetic 
means, standard deviations, and geometric means for each time point. The PK parameters  
will be computed using WinNonlin (Version 6.3, Princeton, NJ) or other appropriate 
software. The relationship between each of these PK parameters and dosage will be 
evaluated and summarized  (Table 3). 
  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 81 of 93 Table 3 Parameters for Serum PER977 and BAP 
Parameter  Units  Description  
Cmax ng/mL  Maximum concentration in the sampled matrix, obtained 
directly from the observed concentration versus time data  
C24 ng/mL  Observed quantifiable analyte concentration in the sampled 
matrix at the [ADDRESS_435306] ng/mL  Last observed quantifiable analyte concentration in the sampled 
matrix  
tlast h Time of C last, obtained directly from the observed concentration 
versus time data  
tmax h Time of C max, obtained directly from the observed 
concentration versus time data  
AUC (0-last) ng⋅h/mL  The area under the concentration -time curve, from time zero to 
the last quantifiable concentration (C last) 
AUC (0-inf)  ng⋅h/mL  Area under the concentration -time curve in the sampled matrix 
from zero (predose) extrapolated to infinite time by [CONTACT_350074]:  
AUC (0-last) + C last/λz  
λz 1/h Apparent terminal rate constant  
t1/[ADDRESS_435307](2)/ λz 
CL L/h Systemic clearance after IV dosing, calculated for PER977 only  
Vz L Volume of distribution after IV dosing, calculated for PER977 
only 
Vss L Steady -state volume of distribution after IV dosing, calculated 
for PER977 only  
MR Cmax  Metabolite to parent (BAP/PER977) ratio of C max 
MR AUC([ADDRESS_435308])  Metabolite to parent (BAP/PER977) ratio of AUC (0-last) 
MR AUC(0 -inf)  Metabolite to parent (BAP/PER977) ratio of AUC (0-inf) 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 82 of 93 Supporting Pharmacokinetic Parameters  
The following PK parameters for PER977 and its metabolite , BAP , will be calculated for 
diagnostic purposes and listed, but will not be summarized.  
T1/2, Interval  The time interval (h) of the log -linear regression to determine t 1/2 
t1/2, N Number of data points included in the log -linear regression analysis  
Rsq Goodness-of- fit statistic for calculation of λz (regression coefficient)  
%AUC ex Percentage of AUC (0-inf) that is extrapolated from t last to infinity, 
calculated as: 100 x [1 – (AUC last/AUC 0-inf)], where t last is the time of 
the last measurable plasma drug concentration  
 
9.5 Plasma Api[INVESTIGATOR_350059] 24 hours following dose administration of api[INVESTIGATOR_3822] . PK 
parameters will include C max, Tmax, AUC (0-last), t½, Kel, CL/F and Vz/F, if data allow.  
9.6 Dose Proportionality  
The dose proportionality of exposure PK parameters for PER977 and BAP (AUC (0-inf),  
AUC (0-last), and C max), over the administered dose range will be investigated using the 
following power model:  
log (PK parameter) = a + b * log (dose)  
where ‘a’ is the intercept and ‘b’ is the slope. 
Dose proportionality will be assessed graphically and stat istically using the above power 
model approach with the logarithm of PK parameters as the dependent variables and the 
logarithm of the dose as the independent variable for subj ects who  receive one dose at a 
given dose interval. The intercept (a) and the slope (b) together with their 90% CI will be 
estimated and presented for each PK parameter. Parameters ‘ a’ and ‘b’ will be estimated 
using an ordinary least -squares approach or the equivalent. Dose proportionality will be 
declared if  the 90% CI for the slope parameter ‘b’ lie s entirely with in the critical region 
(0.80, 1.25) using the maximal d ose ratio I = 3 (highest dose/lowest dose), a lower 
equivalence limit of 0.80, and an upper equivalence limit of 1.25. 
Additionally, the geometric means for the primary PK parameters between adjacent dose 
levels will be compared using an analysis of covariance (ANCOVA) model including dose, gender and weight as fixed effect s for subjects who receive one administration a t a 
given dose interval. Geometric mean ratios for adjacent adm inistrations (higher 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 83 of 93 dose/lower dose) and correspondi ng 90% CI will be presented. PER977 and BAP 
exposure parameters (C max, AUC (0-inf), and AUC (0-last)) will be plotted vers us dose on 
linear and log -log scales for subjects who receive one administration at a  given dose level 
using a scatterplot with individual exposures, regression line and corresponding 
confidence bands. 
9.[ADDRESS_435309] research organization’s  ( ) SOPs  and Work 
Instructions will be used as the default methodology if not otherwise specified.  All PD 
computations will be performed using Phoenix® WinNonlin® 6.3, or SAS® Version 9.2 
(SAS Institute, Inc., Cary, North Carolina).  Graphics will be prepared with SAS® 
Version 9.2 or SigmaPlot® 12.5.  Actual times will be used in the calculation of PD 
parameters . 
The PD endpoint will be WBCT. The WBCT will be summarized at  observed time  points 
and as change fro m baseline using descriptive statistics and graphical presentations.  
Data handling for PD measurements below the limit of quantitation ( BLQ ) will be  
specified in  the SAP .  In the actual analysis, BLQ values will be set to the lower limit of 
quantitation ( LLOQ ) for PD data summaries and calculations.   
Change- from -baseline and percent -of-baseline will be calculated for all PD endpoints.  
Baseline for all PD endpoints will be defined as the pre- api[INVESTIGATOR_350060] (approximately 
four hours before PER977 or place bo administration  on Day 3).  
The anticoagulant effect of api[INVESTIGATOR_350061]-PER977 (about three hours post-api[INVESTIGATOR_350009] 4 ) versus baseline 
(pre-api[INVESTIGATOR_350062] 1).  For the purposes of the PD analyses, subjects 
with percent -of-baseline WBCT at pre-PER977 <120% (i.e., <20 % increase) will be 
considered as api[INVESTIGATOR_350005]-responders and will be excluded from all PD summaries and 
assessments.  
Listings of individual PD variable collection times, as well as derived sampling time 
deviations (where applicable), will be provided. 
Individual observed and change from baseline values at scheduled time points will be 
summarized by [CONTACT_350075]. In addition, the nature of reve rsal of 
anticoagulation (no effect, partial reversal, complete  or complete and sustained) based on 
the definition of reversal of anticoagulation below using WBCT will be summarized by 
[CONTACT_350075].  

Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 84 of 93 9.8 Analysis of the Primary PD Endpoint (WBCT) 
Definition of Reversal of Anticoagulation  
• Complete reversal is achieved for a treatment group or for a subject if the mean 
WBCT is ≤ 110% of base line at any post -baseline time point up to and including [ADDRESS_435310] is 
<=110% of baseline at any post -baseline time point up to and including [ADDRESS_435311] article administration  
• Complete and sustained reversal of anti- coagulation is achieved for a treatment group 
if the mean  WBCT is ≤ 115% of baseline at all time points between 1 and 5 hours 
(inclusive) following test article administration. Complete and sustained reversal of 
anti-coagulation is achieved for a subject if WBCT is ≤ 115% of baseline at all time 
points between 1 and 5 hours (inclusive) following test article administration    
Statistically Significant Complete Reversal  
• Statistically significant complete reversal, relative to mean placebo WBCT,  is defined 
as p< 0.05, (one tailed) from the comparison of means betwee n treatment and placebo 
at 15, 30, [ADDRESS_435312] Analysis of Variance at study completion.  Distribution diagnostics will be performed to assure assumptions associated with using ANOVA are met . Analysis of 
Means (ANOM) methods will be used to compare means and variances across groups. These methods will be appropriate to test if any of the group means are statistically different from the overall mean or if the group standard deviations are statistically different from the  root mean square error (RMSE). Tukey HSD multiple 
comparison procedure will be used to test for all pairwise differences among the means (Tukey 1953, Kramer 1956). This test is an exact alpha- level test if the sample 
sizes are the same, and conservative if the sample sizes are different (Hayter 1984). 
 
9.[ADDRESS_435313] study drug (PER977 or 
placebo) dose using Phoenix® WinNonlin® (version 6.3 or higher version) or 
SAS® Version 9.2 (SAS Institute, Inc., Cary, North Carolina).  All PD parameters will be 
derived over the time window from the first study drug administration (zero hour) to the last collection (i.e., 24 hours after the final administration of the study drug). 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435314]. 
• Emin: minimum value over the two  minute to 24 hour interval 
• tEmin: time of E min 
• Emin(0-6h): minimum value over the two minute to six hour interval post-final dose 
• tEmin(0-6h): time of E min(0-6h) 
• Emax: maximum value over the two  minute to 24 hour interval 
• tEmax: time of E max 
• ΔEmax: maximum value minus the  baseline value (observed only) 
9.[ADDRESS_435315] will be listed.  
9.11 Safety Endpoints 
Individual vital signs, ECG parameters, and clinical laboratory data will be listed and tabulated with descriptive statistics.  For the laboratory safety data, out of range values will be tabulated in shift tables.  Abnormal and clinically noteworthy ECGs will be tabulated. 
Treatment -emergent AEs will be tabulated by [CONTACT_184768], and further by [CONTACT_184769].  SAEs and adverse events that lead to discontinuation will be listed.  
Physical examination results will be listed.  New onset abnormalities after dosing will be recorded as adverse events.  
9.12 Interim Analysis 
No formal interim analyses are planned.  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435316] their origin in the Declaration of Helsinki, the ICH consolidated Guideline E6 for GCP (CPMP/ICH/135/95), and applicable regulatory requirement(s) and FDA GCP 
Regulations: Code of Federal Regulations (CFR) Title 21, parts 11, 50, 54, [ADDRESS_435317]’s participation in the study, it is the Investigator or designee’s responsibility to obtain freely given consent, in writing, from the subject after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol- specific screening procedures or any study drugs are 
administered.  The written ICF must be prepared in the local language(s) of the potential subject population. 
In obtaining and documenting informed consent, the Investigator or designee must 
comply with the applicable r egulatory requirements, and must adhere to GCP and to the 
ethical principles that have their origin in the Declaration of Helsinki.  The consent form and any revision(s) must be approved by [CONTACT_1201]/IEC prior to being provided to potential subjects.  
The subject’s written informed consent must be obtained prior to his/her participation in the study, and must be documented in the subject’s medical records, as required by [ADDRESS_435318], and by [CONTACT_28490] (not necessarily the Investigator).  The original signed ICF must be retained in accordance with institutional policy, and a copy of the signed consent form must be provided to the subject or legal representative.  The date and time (if applicable) that informed consent was given must be recorded on the CRF. 
If the subject cannot read, then according to ICH/GCP Guideline, Section 4.8.9, an 
impartial witness should be present during the entire informed consent discussion.  This witness should sign the ICF after the subject or the legally acceptable representative has orally consented to the subject’s participation and, if possible, signed the ICF.  By [CONTACT_12568], the witness attests that the inform ation in the ICF and any other written 
information was adequately explained to and apparently understood by [CONTACT_184770].  
Additional consent is required for the Health Insurance Portability and Accountability Act (HIPAA).  
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 89 of 93 10.6 Patient Confidentiality 
The Investigators, the Clinical Research Organization (CRO)  and the Sponsor 
(Perosphere)  will preserve the confidentiality of a ll subjects taking part in the study, in 
accordance with GCP and local regulations.  
The Investigator must ensure that the subject’s anonymity is maintained.  On the CRFs or 
other documents submitted by  [CONTACT_350076] a 
unique subject identifier as de fined  by [CONTACT_456].  Documents that are not for 
submission to other entities  (e.g., signed ICFs) should be kept in strict confidence by [CONTACT_3786]. 
In compliance with US Federal regulations and ICH/GCP Guidelines, it is required that 
the Investigator and institution permit authorized representatives of the company, of the regulatory agency(s), and the IRB /IEC  direct access to review the subject’s original 
medical records for verification of study- related procedures and  data.  The Investigator is 
obligated to inform the subject that his/her study -related records will be reviewed by [CONTACT_184772]. 
10.[ADDRESS_435319] recruitment procedures (e.g., advertisements), information about payments and compensation available to the subjects and documentation evidencing the Investigator’s qualifications should be submitted to the IRB/IEC for ethical review and approval according to local regulations, prior to the study start.  The written approval should identify all documents reviewed by [CONTACT_152872]. 
Changes in the conduct of the study or planned analysis will be documented in a protocol 
amendment and/or the SAP.  
The Investigator must submit and, where necessary, obtain approval from the IRB/IEC and/or Sponsor for all subsequent protocol amendments and changes to the informed consent document or changes of the investigational site, facilities or personnel.  The Investigator should notify the IRB/IEC of deviations from the protocol or SAEs occurring at the site and other  AE reports received from the CRO, in accordance with local 
procedures. 
As required by [CONTACT_427], the Sponsor’s local Regulatory Affairs group will insure 
all legal aspects are provided, and approval of the appropriate regulatory bodies obtained, prior to study initiation, and that implementation of changes to the initial protocol and other relevant study documents happen only after the appropriate notification of or approval by [CONTACT_184773]. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-011 02May2019 
Confidential  Page 90 of 93 10.8 Case Report Forms and Study Records  
Study data will be recorded using electronic data capture (EDC).   
10.9 Protocol Violations/Deviations 
The Investigator should conduct the study in compliance with the protocol agreed to by 
[CONTACT_184774], if required, by [CONTACT_46962](ies), and which was given approval/favorable opi[INVESTIGATOR_1686]/IEC. 
A deviation to any protocol procedure or waiver to any stated criteria will not be allowed 
in this study except where necessary to eliminate immediate hazard(s) to the subject.  Perosphere must be notified of all intended or unintended deviations to the protocol (e.g., inclusion/exclusion criteria, dosing, missed study visits) on an expedited basis. 
The Investigator, or person designated by [CONTACT_737], should document and explain 
any deviation from the approved protocol. 
If a subject was ineligible or received the incorrect dose or investigational treatment, and 
had at least one administration of investigational product, data should be collected for safety purposes. 
The Investigator should notify the IRB/IEC  of deviations from the protocol in accordance 
with local procedures.  
10.10  Financial Disclosure 
Prior to starting the study, the Principal Investigator [INVESTIGATOR_1238]/or institution will sign a clinical 
study agreement with Perosphere.  This agreement will include financial information agreed upon by [CONTACT_184775] (if applicable) and conflict of 
interest on the part of the clinical investigator, sub -investigator, their spouses and 
dependent children.  
10.11  Publication and Disclosure Policy 
A study site may not publish results of a study without the written permission of Perosphere and provided that Perosphere has had the opportunity to review and approve the study site’s proposed publication prior to its being submitted. 
10.12  Reimbursement, Indemni ty, and Insurance  
Reimbursement, indemnity and insurance shall be addressed in a separate agreement on terms agreed upon by [CONTACT_46954]. 
Ciraparantag  Perosphere Inc.  
Clinical Trial Protocol: PER977 -02-[ADDRESS_435320] of Edoxaban.  New Eng J Med. 2014, 371:2141-2142. Epub. November 5.  DOI:10.1056/NEJMc1411800 
Centers for Disease Control and Prevention.  Venous thromboembolism: A public health 
concern.  Available at: http://www.cdc.gov/NCBDDD/dvt/data.html  Accessed on January 13, 2014. 
Department of Health and Human Services.  Centers for Disease Control. Atrial 
Fibrillation  Fact Sheet.  
http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/docs/fs_atrial_fibrillation.pdf Accessed January 13, 2014. 
Institute List of High -Alert Medications.  Available at: 
http://www.ismp.org/Tools/highalertmedications.pdf.  Accessed January 13, 2014. Number, rate and standard error of all listed surgical and nonsurgical procedures for 
discharges from short- stay hospi[INVESTIGATOR_350063], [LOCATION_002] 
2010.  Available at:  http://www.cdc.gov/nchs/data/nhds/4procedures/2010pro4_numberrate.pdf  Accessed on January 13, 2014 . 
MacLean S, Mulla S, Aki EA, et al.  Patient values and preferences in decision making 
for antithrombotic therapy: a systematic review: Antithrombotic  therapy and prevention 
of thrombosis, [ADDRESS_435321]. 2012;141 ([ADDRESS_435322]):e1S-e23S. 
Palareti G.  Bleeding with anticoagulant treatments.  H amostaseologie.  2011;Vol 4.  
Safety Alerts for Human Medical Products. Pradaxa (dabigatran etexilate mesylate): 
Drug Safety Communication - Safety Review of Post -Market Reports of Serious 
Bleeding Events.   
http://www.fda.gov/Safety/MedWatch/SafetyInformat ion/SafetyAlertsforHumanMedical
Products/ucm282820.htm?source=govdelivery 
 